var title_f4_20_4416="Evaluation of suspected PH";
var content_f4_20_4416=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Algorithm for investigation of suspected pulmonary hypertension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 561px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PH: pulmonary hypertension; PAH: pulmonary arterial hypertension; ANA: anit-nuclear antibody; RF: rheumatoid factor; ANCA: anti-neutrophil cytoplasmic antibody.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_20_4416=[""].join("\n");
var outline_f4_20_4416=null;
var title_f4_20_4417="Autosomal dominant inheritance";
var content_f4_20_4417=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Dominant inheritance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_20_4417=[""].join("\n");
var outline_f4_20_4417=null;
var title_f4_20_4418="Methemoglobinemia";
var content_f4_20_4418=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Methemoglobinemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the chocolate brown color of methemoglobinemia. Tube 1 and tube 2 have a methemoglobin concentration of 70 percent; tube 3, a concentration of 20 percent; and tube 4, a normal concentration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image reprinted with permission from: Medscape.com, 2011. Available at: file://emedicine.medscape.com/article/956528-overview.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_20_4418=[""].join("\n");
var outline_f4_20_4418=null;
var title_f4_20_4419="Plunging ranula";
var content_f4_20_4419=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plunging ranula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 439px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal computed tomography scan of a large ranula that extends through the mylohyoid musculature of the floor of the mouth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_20_4419=[""].join("\n");
var outline_f4_20_4419=null;
var title_f4_20_4420="Heart conduction system PI";
var content_f4_20_4420=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F71235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F71235&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    The conduction system of the heart",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The heart has its own built-in electrical system, called the conduction system. The conduction system sends electrical signals throughout the heart that determine the timing of the heartbeat and cause the heart to beat in a coordinated, rhythmic pattern. The electrical signals, or impulses, of the heart are generated by a clump of specialized tissue called the sinus node. Each time the sinus node generates a new electrical impulse, that impulse spreads out through the heart's upper chambers, called the right atrium and the left atrium. This electrical impulse, as it spreads across the two atria, stimulates them to contract, pumping blood into the right and left ventricles. The electrical impulse then spreads to the atrioventricular (AV) node, which is another clump of specialized tissue located between the atria and the ventricles. The AV node momentarily slows down the spread of the electrical impulse, to allow the left and right atria to finish contracting. From the AV node, the impulse spreads into a system of specialized fibers called the His bundle and the right and left bundle branches. These fibers distribute the electrical impulse rapidly to all areas of the right and left ventricles, stimulating them to contract in a coordinated way. With this contraction, blood is pumped from the right ventricle to the lungs, and from the left ventricle throughout the body.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_20_4420=[""].join("\n");
var outline_f4_20_4420=null;
var title_f4_20_4421="Hydrocodone and pseudoephedrine: Patient drug information";
var content_f4_20_4421=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hydrocodone and pseudoephedrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23910?source=see_link\">",
"     see \"Hydrocodone and pseudoephedrine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F180237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rezira&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop coughing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hydrocodone, pseudoephedrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3504383",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Glaucoma, very bad heart disease, high blood pressure, or urinary tract block.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705867",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Measure liquid doses carefully. Use the measuring device that comes with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10742 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.248.109.99-A662985E8F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_20_4421=[""].join("\n");
var outline_f4_20_4421=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180237\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021392\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021394\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021393\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021398\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021399\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021401\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021396\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021397\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021402\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021403\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23910?source=related_link\">",
"      Hydrocodone and pseudoephedrine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_20_4422="Incidental Meckels on CT scan";
var content_f4_20_4422=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    Incidental Meckels on CT scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Incidental note of a noninflamed Meckel's diverticulum (arrow) in the axial view (A) and coronal reconstruction (B) of the abdominal CT scan.",
"    <div class=\"footnotes\">",
"     CT: computed tomography",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_20_4422=[""].join("\n");
var outline_f4_20_4422=null;
var title_f4_20_4423="CIN terminology and histology";
var content_f4_20_4423=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 633px\">",
"   <div class=\"ttl\">",
"    Terminology and histology of cervical intraepithelial neoplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 613px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Terminology regarding cytologic and histologic precancerous changes of the uterine cervix. The corresponding terminology from the previous classification system to the current system (initiated with the Bethesda 1988 report) is shown. Images of the histologic correlates for each category are also shown.",
"    <div class=\"footnotes\">",
"     LSIL: low grade squamous intraepithelial neoplasia; HSIL: high grade squamous intraepithelial neoplasia; CIN: cervical intraepithelial neoplasia.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Solomon D, et al. JAMA 2002; 287:2114.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_20_4423=[""].join("\n");
var outline_f4_20_4423=null;
var title_f4_20_4424="Approach to the patient with chronic meningitis";
var content_f4_20_4424=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with chronic meningitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/20/4424/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/20/4424/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/20/4424/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/20/4424/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/20/4424/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/20/4424/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/20/4424/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningitis can be classified on the basis of its underlying cause, type of inflammatory response, or the time course of the illness. Based upon the time course, meningitis is defined as acute or chronic. The onset of symptoms of acute meningitis typically is abrupt with progression over hours, but some patients become ill over several days, especially when early symptoms are not appreciated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute meningitis due to infectious causes usually does not recur. However, a small number of patients with acute meningitis may develop recurrent attacks between intervals of good health. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/26/43433?source=see_link&amp;anchor=H26#H26\">",
"     \"Approach to the adult with recurrent infections\", section on 'Meningitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic meningitis is arbitrarily defined as meningitis lasting for four weeks or more and is a complex entity with both infectious and noninfectious causes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. Although some authors attempting to define the syndrome of chronic meningitis have excluded patients with meningitis occurring concurrently with mass lesions of the central nervous system, meningitis associated with previously diagnosed systemic diseases known to cause meningitis, and meningitis following neurosurgical procedures, this definition may be too restrictive for clinical purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients with chronic meningitis usually have a subacute onset of symptoms including fever, headache, and vomiting. The symptoms can remain static, fluctuate,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    slowly worsen. The symptoms and clinical course of chronic meningitis vary widely from patient to patient.",
"   </p>",
"   <p>",
"    The differential diagnosis, clinical evaluation, prognosis, and management strategies for patients with chronic meningitis, including those in whom a diagnosis cannot be established with routine tests, will be reviewed here. Individual conditions associated with chronic meningitis are discussed separately. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LIMITATIONS OF THE LITERATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of its rarity and the diversity of causes, the literature on chronic meningitis consists largely of case reports and a small number of retrospective case series from single centers. Selection and ascertainment basis greatly limit the utility of this literature for assessing the relative proportions of patients with any given etiologic diagnosis and for assessing the natural history of individual patients with chronic meningitis.",
"   </p>",
"   <p>",
"    Most of these case series describe patients from referral centers or geographic areas where selection bias was likely because of unique patient populations or because of local referral patterns. For example, one case series summarizing the clinical features of 83 patients with chronic meningitis collected over a 16-year period in a referral hospital in New Zealand reported that 40 percent of patients had tuberculous meningitis and that an additional 17 percent of patients responded to empiric antituberculous therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/9\">",
"     9",
"    </a>",
"    ]. However, most of the patients with tuberculosis (TB) described in this report were indigenous Maori people or Pacific island residents.",
"   </p>",
"   <p>",
"    In another report describing 114 consecutive patients with chronic meningitis admitted to a Bangkok hospital, tuberculosis was responsible for 37 percent of cases and Cryptococcus neoformans was the etiologic agent in 54 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/10\">",
"     10",
"    </a>",
"    ]. A high proportion of these patients had HIV infection and the presence or absence of HIV infection had a major impact on the likelihood that a specific pathogen would be found. Similar problems related to selection or ascertainment bias make it difficult to interpret reports concerning the utility of various diagnostic tests in patients with chronic meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;An array of infectious agents can present as chronic meningitis, but a nearly identical syndrome can result from a number of inflammatory, malignant, or other noninfectious diseases (",
"    <a class=\"graphic graphic_table graphicRef76402 \" href=\"UTD.htm?28/54/29549\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Despite extensive testing, an etiologic diagnosis may not be determined in up to one-third of all patients.",
"   </p>",
"   <p>",
"    The initial evaluation of patients with chronic meningitis is often complex and difficult. In some cases, the diagnosis is first suspected and later confirmed because of subtle historical or epidemiologic clues, or associated clinical findings that at first glance may seem to be incidental. For example, the presence of iritis or uveitis or the finding of localized cutaneous lesions may provide a crucial clue to the presence of diseases, such as sarcoidosis, Behcet&rsquo;s disease, uveo-meningitis syndromes, or a systemic fungal infection that initially manifested as chronic meningitis. Similarly, the simultaneous presence of deafness and optic neuritis and uveitis are strong clues to a diagnosis of Vogt-Koyanagi-Haradi syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical symptoms of patients with chronic meningitis rarely point to a specific etiologic diagnosis. However, occasionally a historical or epidemiologic clue can lead to the discovery of an otherwise obscure diagnosis (",
"    <a class=\"graphic graphic_table graphicRef67355 \" href=\"UTD.htm?19/4/19532\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of travel to the southwestern United States or southern California can be a crucial clue to the presence of coccidioidomycosis in a patient with chronic meningitis residing in a non-endemic area. Sometimes the history of travel may be distant, forgotten, or deemed to be inconsequential. For example, patients with coccidioidomycosis may acquire their infection after short stays in airports in endemic areas, and such information may be missed unless a meticulous history is obtained. Thus, all patients with chronic meningitis should be questioned about travel or residence in geographic areas known to be endemic for coccidioidomycosis, histoplasmosis, paracoccidioidomycosis, blastomycosis, schistosomiasis, trypanosomiasis, angiostrongylus cantonensis infection, or cysticercosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17271?source=see_link\">",
"     \"Coccidioidal meningitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43112?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of disseminated histoplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A past history of a positive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    or of a known exposure to TB may be enough justification to institute empiric therapy for tuberculous meningitis or to pursue this diagnosis further with special cultures or testing based upon polymerase chain reaction (PCR) technology, especially if preexisting infection with HIV is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28713?source=see_link\">",
"     \"Central nervous system tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The immune status of all patients with chronic meningitis should be assessed by both history and laboratory testing. Patients should be questioned about risk factors for both human immunodeficiency virus (HIV) and human T-lymphotropic virus (HTLV)-I and II (eg, a history of injection drug use, sexual promiscuity) and about possible or known exposure to syphilis. Lyme disease is a rare cause of chronic meningitis, but patients should be asked about a past history of skin lesions typical or suggestive of erythema migrans or travel to or contact with ticks in an endemic area for Borrelia burgdorferi infection.",
"   </p>",
"   <p>",
"    A careful review of all recent medications including the use of immunosuppressive drugs, immunoglobulin therapy, and nonsteroidal antiinflammatory (NSAIDs) agents should be undertaken. Patients should be questioned about contact with animals, including cats and wild game, or meat processing. The presence or absence of systemic symptoms suggesting a vasculitic disorder, such as granulomatosis with polyangiitis (Wegener&rsquo;s), systemic lupus erythematous, or Behcet's syndrome, should be sought. For example, a history of iritis, recurrent genital or oral ulcers, or of nasal inflammation may lead to a diagnosis of Behcet's disease.",
"   </p>",
"   <p>",
"    The presence of systemic symptoms such as weight loss, unexplained cough, or night sweats may be difficult to assess, since such symptoms can occur as a consequence of chronic meningitis or be related to an underlying malignancy that is the primary cause of the inflammatory reaction in the central nervous system (CNS).",
"   </p>",
"   <p>",
"    Careful questioning about the onset of symptoms is important, as it can help to determine if symptoms are intermittent (ie, more compatible with recurrent meningitis) or continuous. This determination occasionally can be difficult if symptoms in patients with chronic meningitis fluctuate over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic meningitis typically undergo an array of complex diagnostic investigations including serologic assays, multiple imaging tests, and repeated lumbar punctures (",
"    <a class=\"graphic graphic_table graphicRef64041 \" href=\"UTD.htm?19/59/20412\">",
"     table 3",
"    </a>",
"    ). The complexity of the diagnostic work-up is illustrated by a report summarizing the diagnostic testing of 37 consecutive patients with chronic idiopathic meningitis evaluated at the Mayo Clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/12\">",
"     12",
"    </a>",
"    ]. Despite a total of 2295 tests of 44 different types performed on the CSF of these 37 patients, a diagnosis was rarely made.",
"   </p>",
"   <p>",
"    The type of laboratory testing should be based upon the clinical features of an individual case and the subsequent probability that a specific disease is present. For example, routine evaluation of patients with chronic meningitis usually includes tuberculin skin tests, a chest x-ray and serologic testing for syphilis, and testing for the presence of HIV infection. However, tests for unusual infectious diseases such as Lyme disease, cysticercosis, trypanosomiasis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    schistosomiasis are only necessary in patients in whom there is reasonable pre-test probability that the disease or condition is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     CSF examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of CSF reveals abnormalities in patients with chronic meningitis, but these abnormalities are rarely diagnostic with some notable exceptions. The presence of eosinophilia can provide an important clue to the presence of a parasitic etiology or coccidioidomycosis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40632?source=see_link\">",
"     \"Eosinophilic meningitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17271?source=see_link\">",
"     \"Coccidioidal meningitis\"",
"    </a>",
"    ). Similarly, stained smears of a centrifuged sample of the CSF may occasionally reveal infectious agents, such as fungi or bacteria and thus lead to a specific etiologic diagnosis.",
"   </p>",
"   <p>",
"    Antigen testing of the CSF for the presence of C. neoformans and a VDRL test for syphilis should be performed on all patients with chronic meningitis. The sensitivity and specificity of such testing for cryptococcal meningitis is extremely high [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/5\">",
"     5",
"    </a>",
"    ]; however, capsule-deficient strains of C. neoformans can rarely cause a false-negative antigen test [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of late syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with chronic meningitis have a predominance of lymphocytes, although a small percentage of patients have a predominance of neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/14\">",
"     14",
"    </a>",
"    ]. The differential diagnosis of chronic meningitis with a neutrophil predominance includes nocardiosis, brucellosis, and the endemic mycoses (",
"    <a class=\"graphic graphic_table graphicRef74697 \" href=\"UTD.htm?18/29/18907\">",
"     table 4",
"    </a>",
"    ). Nontuberculous mycobacteria can also cause chronic meningitis associated with a predominantly neutrophilic response in some cases; and with a lymphocytic response in others. Acid fast bacilli are usually not detectable in stains of CSF in such patients. Occasionally gram-positive rods may be visualized in the CSF of patients with chronic meningitis due to nontuberculous mycobacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/15\">",
"     15",
"    </a>",
"    ]. Most of the case reports describing chronic meningitis due to nontuberculous mycobacteria involved patients with a prior history of trauma or neurosurgery but occasionally CNS infections have arisen secondary to otitis media or secondary to disseminated infections such as endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28713?source=see_link\">",
"     \"Central nervous system tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A sample of CSF should be submitted for cultures using media appropriate for aerobic bacteria, mycobacteria, and fungi. If routine cultures are negative, it is sometimes useful to send 10 to 20 mL of CSF to the microbiology laboratory with instructions to culture the entire sample on appropriate media. This may be particularly useful if fungal meningitis is suspected (eg, in neurosurgical or immunocompromised patients), since the organism may be present in low numbers and the yield of standard cultures of CSF is poor. PCR testing of a sample of CSF using primers specific for Mycobacterium tuberculosis may be useful in some cases, but such testing is not highly sensitive and inter- and intra-laboratory variability of test results remains a problem [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/16\">",
"     16",
"    </a>",
"    ]. Whipple&rsquo;s disease has been rarely associated with chronic meningitis and in such cases PCR testing of cerebrospinal fluid has been diagnostic [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a fungal pathogen is suspected, cultures of blood and urine should be submitted to the laboratory along with notification that fungi are possible pathogens so that appropriate media and techniques can be utilized. For example, isolator blood cultures that utilize lysis centrifugation may rarely be useful in patients with chronic meningitis due to an underlying fungal or mycobacterial infection. If brucellosis is suspected on the basis of epidemiologic clues such as exposure to unpasteurized milk or milk products, blood and CSF should be cultured using media incubated in a high concentration of carbon dioxide for three weeks, and serum should be tested for the presence of anti-brucella antibodies.",
"   </p>",
"   <p>",
"    If routine tests fail to disclose a likely pathogen or a likely cause for the meningitis, at least 20 to 30 mL of CSF should also be sent for cytologic examination, flow cytometry, and immunoglobulin heavy-chain rearrangement studies by polymerase chain reaction. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\", section on 'Cerebrospinal fluid analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum antibody tests studies for fungal pathogens may not accurately detect the presence of a fungal pathogen in the CSF. Some patients with meningitis due to H. capsulatum, for example, do not have detectable antibody titers in the serum, yet antibodies against H. capsulatum can be detected in the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/18\">",
"     18",
"    </a>",
"    ]. Similarly detection of meningitis due to Sporothrix may not be possible unless specific serologic testing for sporotrichosis is performed on the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/19\">",
"     19",
"    </a>",
"    ]. Serologic testing of serum for antibodies to Brucella, Ehrlichia, and T. gondii can rarely yield a diagnosis in a patient with chronic meningitis, but a single positive antibody test may not be diagnostic of active infection.",
"   </p>",
"   <p>",
"    Although CSF obtained from the lumbar space is usually adequate to diagnose most causes of meningitis, obtaining spinal fluid from the ventricular space for the examination may be useful in rare cases (eg, patients with ventriculitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/13,20\">",
"     13,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) and computed tomography (CT) are useful in the evaluation of patients with chronic meningitis, but these imaging techniques lead to specific diagnosis in a minority of patients. However, such imaging is important since it can exclude important abnormalities such as a parameningeal focus of infection, abscess, or a tumor. Rarely, such imaging may disclose one of these processes or the cystic changes typical of cysticercosis. Some patients with chronic meningitis have focal or diffuse areas of meningeal enhancement, a finding not normally diagnostic of any specific entity. However, such focal abnormalities, when present, can be useful in selecting the site for brain biopsy if the usual diagnostic testing methods are not positive and if deterioration occurs during follow-up.",
"   </p>",
"   <p>",
"    Brain imaging can also detect hydrocephalus that may require shunts or other neurosurgical procedures, particularly if patients are symptomatic from increased intracranial pressure and if symptoms persist after empiric or directed medical therapy. MRI of the spinal cord and spinal axis may occasionally be useful in patients with signs or symptoms of spinal cord dysfunction or back pain. Cerebral angiography may be diagnostic in up to two-thirds of patients with granulomatous angiitis of the CNS; however, neither a normal angiogram nor a negative cerebral biopsy can reliably rule out this rare condition [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25386?source=see_link\">",
"     \"Primary angiitis of the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chest radiographs should be obtained in all patients with chronic meningitis. Such radiographs can lead to a diagnosis such as TB, sarcoidosis, a systemic fungal infection, or a malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Role of meningeal or brain biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain and meningeal biopsy may be useful in patients who have a progressive deteriorating course despite empiric therapy, particularly if focal findings are detected on brain imaging. Several studies have examined the yield of meningeal or cortical biopsy in patients with chronic meningitis who are without an etiologic diagnosis after a careful history, clinical examination, and cultures and serologic testing of the CSF. In one case series involving 37 patients with chronic meningitis of unknown cause who eventually underwent a biopsy, a definitive diagnosis was made in 16 of 41 biopsies (39 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/11\">",
"     11",
"    </a>",
"    ]. However, when a biopsy was performed in an area of meningeal enhancement on either MRI or CT, a diagnosis was obtained in 12 of 14 cases (80 percent). In contrast, surgical biopsy was diagnostic in only 2 of 22 cases in which the MRI showed no enhancing regions.",
"   </p>",
"   <p>",
"    The findings in the preceding study are in contrast to earlier studies that failed to show a similarly high yield from meningeal biopsy. For example, meningeal biopsy was diagnostic in only 5 of 25 patients undergoing meningeal or cortical biopsy at a hospital in Auckland, New Zealand during the period from 1967 to 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/22\">",
"     22",
"    </a>",
"    ]. Similar disappointing results were reported from an earlier case series from the same group involving 83 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF PATIENTS WITH CHRONIC MENINGITIS OF UNKNOWN CAUSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Role of empiric therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Antituberculous therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a diagnosis is not established by the above diagnostic modalities and if symptoms are severe or fail to improve after a period of observation, empiric therapy with antituberculous therapy may be useful (even if the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    is negative). Empiric antituberculous therapy may also be warranted for patients with less severe symptoms if epidemiologic factors or clinical findings suggest a high risk for TB (eg, in patients with a past history of direct contact with others with TB or a prior positive tuberculin skin test).",
"   </p>",
"   <p>",
"    In one study including 28 patients with chronic meningitis for whom no cause could be established after a thorough work-up, almost half of the undiagnosed cases responded to empiric antituberculous medications and 11 additional patients had a favorable or complete resolution of symptoms while on antituberculous therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/9\">",
"     9",
"    </a>",
"    ]. Because this study was done in a location where TB was relatively common, this practice may not be applicable in areas with relatively low TB prevalence.",
"   </p>",
"   <p>",
"    Concurrent steroid therapy should ideally be avoided during an empiric trial of antituberculous medication because it may obscure the evaluation of the clinical response. However, in patients with severe symptoms, concurrent steroid therapy is reasonable and appropriate. If no improvement occurs after four to six weeks of empiric antituberculous therapy and if all mycobacterial cultures remain negative, antituberculosis therapy can reasonably be discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric glucocorticoid therapy may be useful in selected patients who fail to improve during follow-up, despite the absence of carefully controlled studies demonstrating benefit in patients with chronic meningitis. Some patients with chronic meningitis in whom an infectious etiology was not detected have responded dramatically to empiric glucocorticoids as illustrated by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 39 patients from the Mayo Clinic with chronic meningitis of unknown cause, symptoms resolved after the institution of glucocorticoid therapy in 19 of the 39 patients (49 percent) despite the fact that a specific cause was not found in any of these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/12\">",
"       12",
"      </a>",
"      ]. The mean duration of symptoms prior to initiating glucocorticoids in this series was 17 months; in some cases symptoms had been present for up to nine years.",
"      <br/>",
"      <br/>",
"      Fourteen of 39 patients (36 percent) remained symptomatic during the follow-up period; symptoms were worse at the end of follow-up in four patients (10 percent). There were no significant differences in the clinical features at the time of initial evaluation between patients who had a poor outcome (ie, death or worsened symptoms during follow up) compared with those whose symptoms resolved, subsided or remained stable during follow-up.",
"      <br/>",
"      <br/>",
"      A cause for chronic meningitis was eventually established in 10 of 49 patients during follow-up. In 4 of these 10 patients a diagnosis was obtained by repeated CSF examination (in which CSF cytology revealed a neoplasm in 4 patients). A total of 21 patients underwent a meningeal or brain biopsy; a diagnosis was obtained in 5 of these 21 patients (neoplasm was present in four of the five positive biopsies).",
"     </li>",
"     <li>",
"      Seven of 17 patients with idiopathic chronic meningitis treated with glucocorticoids maintained their response to treatment after glucocorticoids were withdrawn; treatment durations ranged from six weeks to six years [",
"      <a class=\"abstract\" href=\"UTD.htm?4/20/4424/abstract/23\">",
"       23",
"      </a>",
"      ]. A later diagnosis of granulomatosis with polyangiitis (Wegener&rsquo;s) or multiple sclerosis was made in 2 of these 17 patients. Four patients had a transient response to steroids but later died, and an additional four patients had recurrence of symptoms upon reducing the dose of steroids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Glucocorticoids may have to be slowly tapered and transiently reinstituted since some patients relapse rapidly when steroid therapy is discontinued. Glucocorticoid therapy must be individualized, titrated, or reinstituted if relapse occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Antifungal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric antifungal therapy in patients with chronic meningitis should be used with caution, particularly if there are not compelling clinical or epidemiologic clues pointing to a specific fungal pathogen. Response to such empiric therapy may be hard to assess because patients with fungal meningitis often respond slowly to appropriate therapy and because such therapy can have significant side effects",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obscure the true diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite numerous difficulties in establishing reliable data on prognosis, most patients with chronic meningitis in whom a diagnosis cannot be established after a thorough work-up have a relatively good outcome. Symptoms either resolve or remain stable over follow-up periods, ranging from one to three years. Repeated diagnostic evaluations in this subgroup of patients will reveal a diagnosis in a minority of cases; the most likely diagnosis to be uncovered during follow-up is neoplasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MIMICS OF CHRONIC MENINGITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Mollaret's meningitis, a form of benign recurrent aseptic meningitis, may be mistakenly thought of having chronic meningitis when recurrent attacks occur frequently. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15417?source=see_link&amp;anchor=H7#H7\">",
"     \"Aseptic meningitis in adults\", section on 'Recurrent (Mollaret's) meningitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, patients with viral or postinfectious encephalitis (also known as acute disseminated encephalomyelitis or ADEM), and a small percentage of patients with partially treated bacterial meningitis, may have symptoms lasting for more than a month and thus may be erroneously considered to have chronic meningitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38968?source=see_link&amp;anchor=H3#H3\">",
"     \"Viral encephalitis in adults\", section on 'Viral versus postinfectious encephalitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1060296168\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic meningitis is arbitrarily defined as meningitis lasting for four weeks or more and is a complex entity with both infectious and noninfectious causes. Patients with chronic meningitis usually have a subacute onset of symptoms including fever, headache, and vomiting. The symptoms can remain static, fluctuate,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      slowly worsen. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An array of infectious agents can present as chronic meningitis, but a nearly identical syndrome can result from a number of inflammatory, malignant, or other noninfectious diseases (",
"      <a class=\"graphic graphic_table graphicRef76402 \" href=\"UTD.htm?28/54/29549\">",
"       table 1",
"      </a>",
"      ). Despite extensive testing, an etiologic diagnosis may not be determined in up to one-third of patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical symptoms of patients with chronic meningitis rarely point to a specific etiologic diagnosis. However, occasionally a historical or epidemiologic clue can lead to the discovery of an otherwise obscure diagnosis (",
"      <a class=\"graphic graphic_table graphicRef67355 \" href=\"UTD.htm?19/4/19532\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with chronic meningitis typically undergo an array of complex diagnostic investigations including serologic assays, multiple imaging tests, and repeated lumbar punctures (",
"      <a class=\"graphic graphic_table graphicRef64041 \" href=\"UTD.htm?19/59/20412\">",
"       table 3",
"      </a>",
"      ). The type of laboratory testing should be based upon the clinical features of an individual case and the subsequent probability that a specific disease is present. For example, routine evaluation of patients with chronic meningitis usually includes tuberculin skin tests, a chest x-ray and serologic testing for syphilis, as well as testing for the presence of HIV infection. However, tests for unusual infectious diseases, such as Lyme disease, cysticercosis, trypanosomiasis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      schistosomiasis, are only necessary in patients in whom there is reasonable pretest probability that the disease or condition is present. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Analysis of cerebrospinal fluid (CSF) reveals abnormalities in patients with chronic meningitis, but these abnormalities are rarely diagnostic with some notable exceptions. The presence of eosinophilia can provide an important clue to the presence of a parasitic etiology or coccidioidomycosis. Similarly, stained smears of a centrifuged sample of the CSF may occasionally reveal infectious agents, such as fungi or bacteria, and thus lead to a specific etiologic diagnosis. Antigen testing of the CSF for the presence of C. neoformans and a VDRL test for syphilis should be performed on all patients with chronic meningitis. A sample of CSF should be submitted for cultures using media appropriate for aerobic bacteria, mycobacteria, and fungi. Other studies that should be obtained are discussed above (See",
"      <a class=\"local\" href=\"#H7\">",
"       'CSF examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) and computed tomography (CT) are useful in the evaluation of patients with chronic meningitis, but these imaging techniques lead to specific diagnosis in a minority of patients. However, such imaging is important since it can exclude important abnormalities, such as a parameningeal focus of infection, abscess, or a tumor. Rarely, such imaging may disclose one of these processes or the cystic changes typical of cysticercosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brain and meningeal biopsy may be useful in patients who have a progressive deteriorating course despite empiric therapy, particularly if focal findings are detected on brain imaging. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Role of meningeal or brain biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a diagnosis is not established despite a thorough search and if symptoms are severe or fail to improve after a period of observation, empiric therapy with antituberculous therapy may be useful. Empiric antituberculous therapy may also be warranted for patients with less severe symptoms if epidemiologic factors or clinical findings suggest a high risk for TB (eg, in patients with a past history of direct contact with others with TB or a prior positive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       tuberculin skin test",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Antituberculous therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Empiric glucocorticoid therapy may be useful in selected patients who fail to improve during follow-up, despite the absence of carefully controlled studies demonstrating benefit in patients with chronic meningitis. Some patients with chronic meningitis in whom an infectious etiology was not detected have responded dramatically to empiric glucocorticoids. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/1\">",
"      Hopkins AP, Harvey PK. Chronic benign lymphocytic meningitis. J Neurol Sci 1973; 18:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/2\">",
"      Ellner JJ, Bennett JE. Chronic meningitis. Medicine (Baltimore) 1976; 55:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/3\">",
"      Adey G, Wald SL. Chronic or recurrent meningitis. Neurosurgical perspectives. Neurosurg Clin N Am 1992; 3:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/4\">",
"      Coyle PK. Overview of acute and chronic meningitis. Neurol Clin 1999; 17:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/5\">",
"      Hildebrand J, Aoun M. Chronic meningitis: still a diagnostic challenge. J Neurol 2003; 250:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/6\">",
"      Tan TQ. Chronic meningitis. Semin Pediatr Infect Dis 2003; 14:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/7\">",
"      Helbok R, Broessner G, Pfausler B, Schmutzhard E. Chronic meningitis. J Neurol 2009; 256:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/8\">",
"      Cohen BA. Chronic meningitis. Curr Neurol Neurosci Rep 2005; 5:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/9\">",
"      Anderson NE, Willoughby EW. Chronic meningitis without predisposing illness--a review of 83 cases. Q J Med 1987; 63:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/10\">",
"      Helbok R, Pongpakdee S, Yenjun S, et al. Chronic meningitis in Thailand. Clinical characteristics, laboratory data and outcome in patients with specific reference to tuberculosis and cryptococcosis. Neuroepidemiology 2006; 26:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/11\">",
"      Cheng TM, O'Neill BP, Scheithauer BW, Piepgras DG. Chronic meningitis: the role of meningeal or cortical biopsy. Neurosurgery 1994; 34:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/12\">",
"      Smith JE, Aksamit AJ Jr. Outcome of chronic idiopathic meningitis. Mayo Clin Proc 1994; 69:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/13\">",
"      Sugiura Y, Homma M, Yamamoto T. Difficulty in diagnosing chronic meningitis caused by capsule-deficient Cryptococcus neoformans. J Neurol Neurosurg Psychiatry 2005; 76:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/14\">",
"      Peacock JE Jr, McGinnis MR, Cohen MS. Persistent neutrophilic meningitis. Report of four cases and review of the literature. Medicine (Baltimore) 1984; 63:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/15\">",
"      Talati NJ, Rouphael N, Kuppalli K, Franco-Paredes C. Spectrum of CNS disease caused by rapidly growing mycobacteria. Lancet Infect Dis 2008; 8:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/16\">",
"      Noordhoek GT, Kolk AH, Bjune G, et al. Sensitivity and specificity of PCR for detection of Mycobacterium tuberculosis: a blind comparison study among seven laboratories. J Clin Microbiol 1994; 32:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/17\">",
"      Marumganti AR, Murphy TF. Whipple's disease: neurological relapse presenting as headache for two years. J Gen Intern Med 2008; 23:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/18\">",
"      Wheat LJ, Batteiger BE, Sathapatayavongs B. Histoplasma capsulatum infections of the central nervous system. A clinical review. Medicine (Baltimore) 1990; 69:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/19\">",
"      Scott EN, Kaufman L, Brown AC, Muchmore HG. Serologic studies in the diagnosis and management of meningitis due to Sporothrix schenckii. N Engl J Med 1987; 317:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/20\">",
"      Kravitz GR, Davies SF, Eckman MR, Sarosi GA. Chronic blastomycotic meningitis. Am J Med 1981; 71:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/21\">",
"      Calabrese LH, Furlan AJ, Gragg LA, Ropos TJ. Primary angiitis of the central nervous system: diagnostic criteria and clinical approach. Cleve Clin J Med 1992; 59:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/22\">",
"      Anderson NE, Willoughby EW, Synek BJ. Leptomeningeal and brain biopsy in chronic meningitis. Aust N Z J Med 1995; 25:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4424/abstract/23\">",
"      Charleston AJ, Anderson NE, Willoughby EW. Idiopathic steroid responsive chronic lymphocytic meningitis--clinical features and long-term outcome in 17 patients. Aust N Z J Med 1998; 28:784.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1275 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_20_4424=[""].join("\n");
var outline_f4_20_4424=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1060296168\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LIMITATIONS OF THE LITERATURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CSF examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Role of meningeal or brain biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT OF PATIENTS WITH CHRONIC MENINGITIS OF UNKNOWN CAUSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Role of empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Antituberculous therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MIMICS OF CHRONIC MENINGITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1060296168\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1275\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1275|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/54/29549\" title=\"table 1\">",
"      Etiology of chronic meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/4/19532\" title=\"table 2\">",
"      Clues for chronic meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/59/20412\" title=\"table 3\">",
"      Tests for chronic meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/29/18907\" title=\"table 4\">",
"      CSF PMNs chronic meningitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/26/43433?source=related_link\">",
"      Approach to the adult with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15417?source=related_link\">",
"      Aseptic meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28713?source=related_link\">",
"      Central nervous system tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/37/23129?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/2/19494?source=related_link\">",
"      Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=related_link\">",
"      Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17271?source=related_link\">",
"      Coccidioidal meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40632?source=related_link\">",
"      Eosinophilic meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43112?source=related_link\">",
"      Pathogenesis and clinical manifestations of disseminated histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of late syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25386?source=related_link\">",
"      Primary angiitis of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38968?source=related_link\">",
"      Viral encephalitis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_20_4425="Interpersonal Psychotherapy (IPT) for depressed adults: Specific interventions and techniques";
var content_f4_20_4425=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interpersonal Psychotherapy (IPT) for depressed adults: Specific interventions and techniques",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/20/4425/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/20/4425/contributors\">",
"     Holly A Swartz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/20/4425/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/20/4425/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/20/4425/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/20/4425/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/20/4425/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H72107712\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpersonal Psychotherapy (IPT) is a time-limited psychotherapy for treating depression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The therapy focuses upon improving problematic interpersonal relationships or circumstances that are directly related to the current depressive episode. Interpersonal relationships and depressive symptoms appear to affect each other in a reciprocal manner [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Improvement of interpersonal functioning reduces symptoms, which leads to additional spontaneous improvement of interpersonal functioning, which in turn reduces depressive symptoms further.",
"   </p>",
"   <p>",
"    IPT was developed in the 1970s as a treatment for depression and for many years was used only by investigators in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/8\">",
"     8",
"    </a>",
"    ]. Demonstrated success in multiple studies eventually led clinicians to discover that IPT is a practical, user-friendly treatment for many different types of depressed patients, including pregnant, postpartum, or primary care patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuroimaging studies using sequential single photon emission computed tomography (SPECT) and positron emission tomography (PET) suggest that successful treatment of major depression with IPT leads to changes in brain function [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Many of these changes overlap with changes in brain function seen in patients treated with an antidepressant, including regional brain metabolic abnormalities that tended to normalize with treatment.",
"   </p>",
"   <p>",
"    Clinical guidelines suggest IPT monotherapy for treatment of mild to moderate depression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/9,12,13\">",
"     9,12,13",
"    </a>",
"    ]. In addition, IPT is used to treat other psychiatric illnesses, including bipolar disorder, eating disorders, and anxiety disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review specific IPT interventions and techniques for treating depressed adults. The indications, theoretical foundation, general concepts, and efficacy of IPT are discussed separately, as are other treatments of depression. See (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17674?source=see_link\">",
"     \"Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1633421\">",
"    <span class=\"h1\">",
"     THERAPEUTIC STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several therapeutic strategies and procedures are used throughout treatment with Interpersonal Psychotherapy (IPT). These include procedures and themes specific to IPT, as well as techniques that apply to all psychotherapies. In addition, self-report, standardized rating scales are regularly completed by the patient, as is done for any treatment of depression. Some severely ill patients may require both IPT and pharmacotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3946659\">",
"    <span class=\"h2\">",
"     Principles of IPT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain themes and procedures specific to IPT are repeatedly emphasized throughout therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current, upsetting life events trigger depressive episodes in vulnerable patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17674?source=see_link&amp;anchor=H91117012#H91117012\">",
"     \"Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy\", section on 'Link between life events and depression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The symptoms of major depression include feelings of worthlessness and excessive guilt, and patients often blame themselves for their illness and problems. As part of IPT, clinicians strive to help patients view major depression as a treatable medical illness that is not the patient&rsquo;s fault [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/14\">",
"     14",
"    </a>",
"    ]. Consistent with this view, clinicians &ldquo;blame the patient&rsquo;s depression&rdquo; when patients falter in social situations or in treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17674?source=see_link&amp;anchor=H91117005#H91117005\">",
"     \"Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy\", section on 'Medical model'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IPT focuses upon the interpersonal problem area that is most closely linked to the depressive episode. In IPT there are four types of interpersonal problem areas: grief, role disputes, role transitions, and interpersonal deficits. (See",
"    <a class=\"local\" href=\"#H72107843\">",
"     'Select interpersonal problem area and formulate the case'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The clinician explores alternative ways of handling problematic interpersonal situations, and encourages the patient to experiment and make constructive changes in the interpersonal problem area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21428866\">",
"    <span class=\"h2\">",
"     Common therapeutic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians delivering IPT use therapeutic factors that are common to all psychotherapies. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maintaining a warm, supportive, and understanding attitude",
"     </li>",
"     <li>",
"      Fostering hope",
"     </li>",
"     <li>",
"      Encouraging patients to express emotions",
"     </li>",
"     <li>",
"      Developing a strong therapeutic alliance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The therapeutic alliance is discussed separately, within the context of psychodynamic psychotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28328?source=see_link&amp;anchor=H114251#H114251\">",
"     \"Depression in adults: Psychodynamic psychotherapy\", section on 'Therapeutic alliance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H478580\">",
"    <span class=\"h2\">",
"     Standardized, self-report rating scale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients complete a self-report, standardized, depression rating scale prior to the beginning of each session. We suggest the widely-used Patient Health Questionnaire &ndash; Nine Item (PHQ-9), which is a well-validated depression self-report scale (",
"    <a class=\"graphic graphic_table graphicRef59307 \" href=\"UTD.htm?14/12/14541\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Alternatives include the Clinically Useful Depression Outcome Scale (CUDOS) (",
"    <a class=\"graphic graphic_form graphicRef65101 \" href=\"UTD.htm?25/29/26065\">",
"     form 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/18,19\">",
"     18,19",
"    </a>",
"    ] and the Quick Inventory of Depressive Symptoms &ndash; Self Report 16 Item (QIDS-SR16) (www.ids-qids.org) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The rating scale quantifies the severity of the patient's depression and enables the clinician to track improvement over time. Changes in symptoms are explicitly linked to changes that patients make in their interpersonal problem area, underscoring the link between depression and interpersonal functioning. Measuring the intensity of symptoms also helps the patient understand that major depression is a real medical illness. In addition, the scale educates patients about the clinical features of depression so that patients can learn to recognize them on their own.",
"   </p>",
"   <p>",
"    Using scales to monitor treatment of depressed patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4745?source=see_link&amp;anchor=H100014116#H100014116\">",
"     \"Using scales to monitor symptoms and treatment of depression (measurement based care)\", section on 'Self-report scales in the public domain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H545430\">",
"    <span class=\"h2\">",
"     Combining IPT with pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For severely depressed patients, combining antidepressant pharmacotherapy and IPT is readily feasible and has been used to good effect in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Combining IPT with pharmacotherapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17674?source=see_link&amp;anchor=H91120529#H91120529\">",
"     \"Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6145003\">",
"    <span class=\"h1\">",
"     DELIVERING INTERPERSONAL PSYCHOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6145110\">",
"    <span class=\"h2\">",
"     Individual versus group format",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpersonal Psychotherapy (IPT) is usually conducted with an individual patient, and most studies have evaluated IPT in this context. However, IPT has been adapted for use in groups [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/25\">",
"     25",
"    </a>",
"    ]. The choice is based upon patient preference and availability of resources.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6145154\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPT was initially delivered in 12 to 16 weekly sessions, each lasting 45 to 50 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/2\">",
"     2",
"    </a>",
"    ]. Shorter courses of treatment have subsequently been used, including an eight-session format [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In practice, the clinician adjusts the number of sessions to meet the needs of the patient and health care setting, but it is important to define from the outset a discrete time frame for treatment. For patients who successfully complete a course of IPT, maintenance treatment may be indicated. (See",
"    <a class=\"local\" href=\"#H72107866\">",
"     'Termination'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    IPT follows a preset structure and limited timeline. The finite duration of treatment is connected to the goal of relieving symptoms quickly. Limiting the amount of time mobilizes and motivates both the clinician and patient to rapidly identify the core problem and change the patient's interpersonal behavior and environment. Unlike open-ended psychotherapies, the clinician does not have the luxury of allowing the therapy to unfold slowly. Thus, IPT focuses upon a relatively narrow interpersonal problem.",
"   </p>",
"   <p>",
"    If there is no significant improvement of depressive symptoms after four to eight weeks of treatment, the clinician should change the treatment plan [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6145212\">",
"    <span class=\"h2\">",
"     Stages of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPT is divided into three phases: initial, middle, and termination. &nbsp;Each phase has specific goals and tasks, and a predetermined duration. The initial phase of IPT lasts up to 3 sessions, the middle phase 10 sessions, and termination 2 to 4 sessions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72107807\">",
"    <span class=\"h3\">",
"     Initial phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial phase of IPT lasts up to three sessions. The different tasks completed in this phase are centered on selecting an interpersonal problem area as the focus of treatment. (See",
"    <a class=\"local\" href=\"#H72107843\">",
"     'Select interpersonal problem area and formulate the case'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The components of the initial phase include (",
"    <a class=\"graphic graphic_table graphicRef78732 \" href=\"UTD.htm?26/55/27516\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diagnosing major depression",
"     </li>",
"     <li>",
"      Giving the patient the sick role",
"     </li>",
"     <li>",
"      Taking an interpersonal inventory",
"     </li>",
"     <li>",
"      Establishing a depression timeline",
"     </li>",
"     <li>",
"      Selecting an interpersonal problem area and formulating the case",
"     </li>",
"     <li>",
"      Providing hope",
"     </li>",
"     <li>",
"      Discussing the treatment contract",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tasks are integrated across the first three treatment sessions. The clinician must collect the relevant information and cover the necessary components, but has considerable latitude in how the process unfolds during the course of the three sessions",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72107815\">",
"    <span class=\"h4\">",
"     Diagnose major depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step is to give the illness a name and diagnose major depression according to DSM-IV-TR criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/28\">",
"     28",
"    </a>",
"    ] or the International Classification of Diseases-10th revision (ICD-10) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/29\">",
"     29",
"    </a>",
"    ]. The diagnosis is based upon the history of current and past psychiatric symptoms, nonpsychiatric medical history, family psychiatric history, current and prior treatment history, and the mental status examination. Laboratory tests should be ordered when indicated to rule out other possible explanations for psychiatric symptoms, such as thyroid function tests to rule out hypothyroidism or a toxicology screen to rule out a substance use disorder. Suicidality is assessed to determine whether hospitalization is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72107822\">",
"    <span class=\"h4\">",
"     Give the patient the sick role",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician gives the patient the sick role, which is a temporarily occupied social role that absolves the patient from responsibilities precluded by the depressive episode [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/14\">",
"     14",
"    </a>",
"    ]. The sick role also requires the patient to assume new responsibilities necessary to treat the depressive illness, such as attending therapy sessions and addressing the identified interpersonal problem area [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/30\">",
"     30",
"    </a>",
"    ]. The sick role follows from the medical model, which states that the patient is not at fault for becoming depressed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72107829\">",
"    <span class=\"h4\">",
"     Take an interpersonal inventory",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interpersonal inventory consists of a comprehensive and detailed assessment of the important relationships in the patient's life and of recent significant changes that have occurred in these relationships and in psychosocial functioning. The clinician asks about:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Confiding relationships",
"     </li>",
"     <li>",
"      Romantic and sexual relationships",
"     </li>",
"     <li>",
"      Daily contacts",
"     </li>",
"     <li>",
"      Family of origin",
"     </li>",
"     <li>",
"      Friends and social supports",
"     </li>",
"     <li>",
"      Conflicted relationships",
"     </li>",
"     <li>",
"      Recent deaths",
"     </li>",
"     <li>",
"      Emotional losses",
"     </li>",
"     <li>",
"      Changes in vocational status",
"     </li>",
"     <li>",
"      Changes in health",
"     </li>",
"     <li>",
"      Changes in housing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In discussing the patient&rsquo;s relationships, the clinician asks about mutual goals, probing specifically for nonreciprocal role expectations in close relationships, ie, disagreements about the expectations of one another. As an example, a wife may wish to equally divide childrearing and financial responsibilities with her husband, whereas the husband may expect the wife to stay at home and assume the majority of childcare responsibilities while he is the primary breadwinner. There are always expectations within a relationship; problems arise when there is a disagreement that cannot be negotiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72107836\">",
"    <span class=\"h4\">",
"     Establish the depression timeline",
"    </span>",
"    &nbsp;&mdash;&nbsp;In taking the history, the clinician establishes a timeline for the current depressive episode by determining when the initial depressive symptoms began and when the depressive syndrome began. For patients who suffer from either chronic depression (major depressive episode lasting more than two years) or \"double depression\" (a major depressive episode that occurs during dysthymia), the clinician determines when the depressive syndrome progressed and became worse [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/31\">",
"     31",
"    </a>",
"    ]. The diagnosis of major depression and dysthymia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnosis of depression\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The changes in interpersonal circumstances (collected in the interpersonal inventory) are superimposed onto the depression timeline. The clinician then determines which interpersonal events are temporally associated with the onset",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    maintenance of the current depressive episode. The interpersonal problem area represented by the life events temporally associated with the depressive episode is selected as the focus of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72107843\">",
"    <span class=\"h4\">",
"     Select interpersonal problem area and formulate the case",
"    </span>",
"    &nbsp;&mdash;&nbsp;One (occasionally two) of four possible interpersonal problem areas is selected as the focus of treatment. In addition, the clinician formulates the case to focus treatment sessions upon the selected problem area to familiarize the patient with the IPT model. &nbsp;",
"   </p>",
"   <p>",
"    According to IPT, depression is caused by a current, unresolved interpersonal problem in at least one of four possible areas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grief &mdash; unresolved mourning for the death of an important person",
"     </li>",
"     <li>",
"      Role dispute &mdash; conflicts with a significant other over different expectations about the relationship",
"     </li>",
"     <li>",
"      Role transition &mdash; difficulty with a major change in the patient&rsquo;s life circumstances",
"     </li>",
"     <li>",
"      Interpersonal deficits &mdash; chronically unfulfilling relationships, pervasive problems starting and maintaining relationships, and social isolation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17674?source=see_link&amp;anchor=H91117026#H91117026\">",
"     \"Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy\", section on 'Interpersonal problem areas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinician selects the interpersonal problem area that is:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temporally associated with the onset or maintenance of the depressive episode as established in the depression timeline",
"     </li>",
"     <li>",
"      Emotionally charged and meaningful to the patient",
"     </li>",
"     <li>",
"      Explicitly acceptable to the patient as a focus for treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The interpersonal deficits problem area is selected only if the patient lacks life events and none of the other three categories is appropriate.",
"   </p>",
"   <p>",
"    The case formulation synthesizes the elements covered in the initial phase [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/32\">",
"     32",
"    </a>",
"    ]. The clinician reviews the patient&rsquo;s diagnosis, explicitly links the interpersonal problem area to the onset of the depressive episode, and obtains explicit agreement from the patient to focus on this problem area for the remainder of treatment. The clinician uses the IPT label to explain the interpersonal problem area (&ldquo;We call this a role dispute&rdquo;), except for the area of interpersonal deficits. Due to the disparaging connotation of the word &ldquo;deficits,&rdquo; clinicians explain this problem area using the term &ldquo;interpersonal sensitivity&rdquo; or &ldquo;social isolation.&rdquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72107850\">",
"    <span class=\"h4\">",
"     Provide hope",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IPT clinician conveys the hopeful message that depression is usually a treatable illness and that the patient can expect to improve over the course of IPT [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/14\">",
"     14",
"    </a>",
"    ]. This optimism is intended to counteract the inherent pessimism of the depressed patient and facilitate the treatment alliance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/33\">",
"     33",
"    </a>",
"    ]. For patients who remain skeptical about improving, the clinician reminds them that hopelessness is a symptom of depression and that other treatment options are available in the event that IPT is not successful. Other treatments for depression are discussed separately. See (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H546973\">",
"    <span class=\"h4\">",
"     Discuss treatment contract",
"    </span>",
"    &nbsp;&mdash;&nbsp;A formal, verbal treatment contract is explicitly discussed. The number of sessions is determined by the clinician and patient, and the clinician explains the principles of IPT, what will occur during the sessions, and what the patient is expected to do. In addition, the clinician should address the logistical aspects of treatment and explicitly state what the policy is for tardiness, missed appointments, emergencies, and payment.",
"   </p>",
"   <p>",
"    If patients are late for a session, the clinician blames the depression rather than the patient (\"when you are depressed, it is hard to get motivated to leave the house\"). However, the clinician also points out the time-limited nature of IPT (\"Unfortunately, we will only be able to meet for the remaining 20 minutes of your session, and there are only have seven sessions left. Let's think together about some strategies that will make it easier for you to get out of the house, even though your mood and energy are low, so we can make the most of our last seven sessions\").",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72107857\">",
"    <span class=\"h3\">",
"     Middle phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The middle phase consists of sessions 4 to 13. During this phase, the clinician and patient work to resolve the selected interpersonal problem area chosen as the treatment focus in the initial phase. Some of the interventions used by the clinician are specific to the selected interpersonal problem area, whereas other procedures are used for all patients, regardless of the problem area (",
"    <a class=\"graphic graphic_table graphicRef59989 \" href=\"UTD.htm?43/4/44108\">",
"     table 3",
"    </a>",
"    ) .",
"   </p>",
"   <p>",
"    Each session seeks to deepen the patient's understanding of the link between current life events and depression, which is accomplished by consistently exploring the link between the patient's symptoms and the selected interpersonal problem area. Focusing upon the problem area is at the core of IPT&rsquo;s structured approach, and clinicians should avoid pursuing interesting clinical material that is extraneous and ultimately a distraction. Post-hoc analysis of a randomized trial found that a more intense focus on the interpersonal problem area was associated with better outcomes for patients receiving IPT [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10707359\">",
"    <span class=\"h4\">",
"     Interventions for each interpersonal problem area",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are specific IPT techniques used with each interpersonal problem area. The definition of each problem area is discussed separately. (See",
"    <a class=\"local\" href=\"#H72107843\">",
"     'Select interpersonal problem area and formulate the case'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21429062\">",
"    <span class=\"h5\">",
"     Grief (complicated bereavement)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician connects the depressive syndrome to feelings about the deceased. Initially, the clinician facilitates the mourning process by systematically asking about the circumstances leading up to the death, events immediately following the death, the patient&rsquo;s role in these circumstances and events, and rituals observed at the time of the death. The relationship with the deceased is reviewed in detail, including both positive and negative aspects.",
"    <br/>",
"    <br/>",
"    The patient may fear the intense emotions associated with grief, and the clinician reassures the patient these feelings are normal and will subside over time. Each session should be paced so that the patient is not overly distraught at the end of the session.",
"    <br/>",
"    <br/>",
"    It may be helpful for patients to visit places associated with the deceased, including the grave; look at photographs or mementos of the individual; write a letter to the deceased; or make a scrapbook. Toward the end of the middle phase, the patient is encouraged to reestablish interest in other people and activities, and to find a substitute for what has been lost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21429079\">",
"    <span class=\"h5\">",
"     Role dispute",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician connects the depressive syndrome to difficulties in a major relationship that stem from different expectations about roles. Initially, the clinician identifies the specifics of the dispute, focuses on the impact of nonreciprocal expectations in the relationship, and examines expectations in other relationships to help the patient understand patterns of behaviors and how the dispute is perpetuated.",
"    <br/>",
"    <br/>",
"    The clinician determines the stage of the dispute and whether the two parties are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Actively negotiating the dispute unsuccessfully",
"     </li>",
"     <li>",
"      Locked in a stalemate (have ceased negotiating)",
"     </li>",
"     <li>",
"      Ready to end the relationship",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depressed patients tend to see hopeless impasses even when it is possible to work things out [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/14\">",
"     14",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    If the two parties are still actively negotiating, better communication is emphasized. If there is an impasse, the clinician attempts to move the patient and other party back to negotiating the dispute, with the warning that &ldquo;things may get worse before they get better.&rdquo; Role playing is helpful for learning better communication skills. (See",
"    <a class=\"local\" href=\"#H10707367\">",
"     'Interventions for any interpersonal problem area'",
"    </a>",
"    below.)",
"    <br/>",
"    <br/>",
"    Whether the two parties are negotiating or at an impasse, it is necessary that they modify their expectations. If this is not possible and they are ready to end the relationship, the clinician frames this as a role transition, with the patient mourning the loss of the old relationship and focusing on new relationships and activities.",
"    <br/>",
"    <br/>",
"    IPT for a role dispute has been described as &ldquo;unilateral couple&rsquo;s therapy&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/35\">",
"     35",
"    </a>",
"    ]. It may be helpful to have the other party attend a single session to educate the individual about depression and to gain a better understanding of the relationship. However, aside from one pilot study [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/36\">",
"     36",
"    </a>",
"    ], IPT has not been conceptualized as couple&rsquo;s therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21429087\">",
"    <span class=\"h5\">",
"     Role transition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <strong>",
"    </strong>",
"    clinician relates the depressive syndrome to difficulties in managing the change from an old role to a new role. Treatment involves helping the patient to accept the new role while developing a more balanced view of the old role.",
"   </p>",
"   <p>",
"    Therapy for role transitions has two parts. Initially, the patient mourns the loss of the old role, which has typically been idealized, and discusses feelings about the change. The old role is likely to have been simplified in the process of idealization, and the patient develops a more complex and \"three dimensional\" view of this role. In the latter part of therapy, the clinician points out opportunities afforded by the new role, which has typically been devalued. In addition, the patient is encouraged to master the skills needed for the new role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21429095\">",
"    <span class=\"h5\">",
"     Interpersonal deficits",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician relates the depressive syndrome to difficulties establishing and maintaining interpersonal relationships. Treatment involves decreasing social isolation by using past relationships and the relationship with the therapist as models for new relationships. The clinician asks about the positive and negative aspects of prior relationships and determines whether any maladaptive patterns occurred. The clinician may also discuss the patient&rsquo;s feelings about the clinician (this represents a departure from what is usually done in IPT), looking for parallels in other relationships. The patient is encouraged to experiment and form new relationships, utilizing every opportunity in the environment, including web-based communication, encounters in stores and coffee shops, and participation in classes and other organized group activities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10707367\">",
"    <span class=\"h4\">",
"     Interventions for any interpersonal problem area",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventions that can be used for any of the four interpersonal problem areas include psychoeducation, communication analysis, role play, exploration of options and decision analysis, and socialization and pleasurable activities.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychoeducation",
"      <strong>",
"      </strong>",
"      &ndash; Education about major depression, including its symptoms, epidemiology, etiology, course of illness, and prognosis. Knowledge about the illness can relieve distress. As an example, knowing the widespread prevalence normalizes the condition, and information about prognosis instills hope.",
"      <br/>",
"      <br/>",
"      In addition, the clinician uses every opportunity to remind the patient that depression is a medical illness with biologic underpinnings [",
"      <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/37\">",
"       37",
"      </a>",
"      ]. When a patient has difficulty accomplishing a task or managing an interpersonal interaction, the clinician generally blames it on the depression, pointing out how the symptoms of depression (anergia, poor concentration, irritability, anhedonia) interfere with functioning. &nbsp;",
"     </li>",
"     <li>",
"      Communication analysis &ndash; Examination and improvement of communication skills. Depressed patients may be irritable and short with others, or withdrawn and slowed down. Impaired communication may be a long-standing problem or may be directly related to the depressive episode.",
"      <br/>",
"      <br/>",
"      Patients describe in detail a conversation with a significant person in their life. The clinician obtains the equivalent of a movie script, complete with details about setting (location, time of day, and who else was present), exact words (\"he said\" then \"she said\" ), tone of voice, and gestures. In addition, the patient describes the feelings that occurred, which the clinician tries to validate. &nbsp;",
"      <br/>",
"      <br/>",
"      After the exchange is reconstructed, the clinician points out the successful and maladaptive aspects, and explores their impact upon the patient&rsquo;s partner. Suggested changes include making direct and positive requests (&ldquo;How about if we see a movie next weekend,&rdquo; rather than &ldquo;I wish you wouldn&rsquo;t play golf every Sunday&rdquo;). In addition, patients are encouraged to articulate their feelings more precisely, listen actively to others, and minimize distractions in their environment when discussing important issues (eg, television or radio).",
"     </li>",
"     <li>",
"      Role play",
"      <strong>",
"      </strong>",
"      &ndash; The clinician and patient rehearse anticipated interactions or replay old, problematic ones. The clinician will typically alternate",
"      <strong>",
"      </strong>",
"      playing the role of the significant other and the role of the patient so that the patient can practice new communication strategies and acquire new skills. Periods of role play alternate with periods of coaching in which the clinician teaches the patient about problematic interactions.",
"     </li>",
"     <li>",
"      Exploration of options and decision analysis &ndash; For any given interpersonal problem, the clinician encourages the patient to consider what solutions are available and to pick one. When the initial response of a",
"      <strong>",
"      </strong>",
"      depressed",
"      <strong>",
"      </strong>",
"      patient is despondency or hopelessness to resolving a problem, the clinician persists and explains that the depression is causing hopelessness and that there are usually options. The clinician may initially need to be active and suggest options, to help the patient generate a list. After evaluating the feasibility of each option, the patient selects a solution for the interpersonal problem. The patient then considers what resources are needed to resolve the problem, creates a plan, and implements it.",
"      <br/>",
"      <br/>",
"      Depressed patients often neglect their own needs and desires because they lack energy, motivation, or interest. Patients are encouraged to think about the outcome they want in an interpersonal problem area. As a result of treatment, the patient may pursue a previously deferred goal (eg, applying for a different job), in which case the clinician will help the patient develop a strategy to achieve the desired goal. Conversely, the patient may decide that it is time to abandon an unattainable goal (eg, an inappropriate romantic interest), in which case the clinician helps the patient mourn the loss of the relinquished object and move on to new goals.",
"     </li>",
"     <li>",
"      Socialization and pleasurable activities &ndash; Socialization and recreation are inherently antidepressant. These activities represent behavioral activation, which is a key active ingredient in cognitive-behavioral therapy and has become a free-standing therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/38\">",
"       38",
"      </a>",
"      ]. Clinicians encourage depressed patients to gradually increase their activity level and social contacts, commensurate with what the depression allows. If a patient is isolated and withdrawn, the therapist may initially suggest limited activities like a walk around the block or an on-line chat group. More socially connected patients are encouraged to increase the frequency of contact with others and broaden their support network.",
"      <br/>",
"      <br/>",
"      Anhedonia may leave patients unable to enjoy any activity. The clinician should explain the symptom and encourage the patient to participate in a potentially pleasurable activity, regardless of the outcome. Even if patients &ldquo;don&rsquo;t feel like it,&rdquo; they should be reassured most people enjoy the particular activity, and instructed to persist with the activity several times. It is less important that patients find the &ldquo;right&rdquo; activity to do and more important that they experiment with some activity. Unlike behavior therapy, IPT clinicians do not assign socialization and pleasurable activities as homework.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72107866\">",
"    <span class=\"h3\">",
"     Termination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Termination comprises the final two to four sessions. IPT likens termination to a graduation. The clinician praises the patient's accomplishments and new skills, and highlights the symptomatic improvement that has occurred over the course of treatment. Credit for these changes is bestowed upon the patient.",
"   </p>",
"   <p>",
"    The clinician actively elicits responses to the end of treatment if the patient does not spontaneously offer them, and encourages the patient to express feelings about ending the relationship with the clinician and moving on. Feelings of sadness about the separation are normalized and distinguished from the pathological symptoms of major depression. Clinicians may acknowledge they will miss working with the patient if this is true, while expressing confidence in the patient&rsquo;s ability to independently remain well.",
"   </p>",
"   <p>",
"    During sessions, the clinician and patient (",
"    <a class=\"graphic graphic_table graphicRef67730 \" href=\"UTD.htm?9/41/9884\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assess treatment progress so that patients can identify interpersonal gains and connect them to reduction of depressive symptoms over the course of therapy. The clinician may wish to re-examine weekly PHQ-9 scores with the patient.",
"     </li>",
"     <li>",
"      Discuss remaining treatment needs and options so that patients can be referred for appropriate follow-up care as needed. The therapy is blamed if the patient has not improved, and the patients are given credit for the efforts they have made.",
"     </li>",
"     <li>",
"      Consider ongoing, monthly, maintenance IPT, which delays or prevents recurrences of major depression [",
"      <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/22,39\">",
"       22,39",
"      </a>",
"      ]. Among the factors to consider in prescribing maintenance IPT are the number of years the patient has had major depression and the number of depressive episodes and hospitalizations that have occurred during that time. The goals for maintenance therapy are to reduce subsyndromal symptoms, maintain recovery from the presenting acute depressive episode, prevent recurrence of new episodes, reduce the risk of suicide, and promote psychosocial functioning.",
"     </li>",
"     <li>",
"      Revisit the link between current life events and depression, in order to anticipate future vulnerability to depression in the face of stressful life events and to develop strategies to minimize the impact of potential stressors.",
"     </li>",
"     <li>",
"      Plan future treatment of depression if the need arises. Clinicians should provide psychoeducation about the risk of recurrence; discuss the concept of early, prodromal symptoms; encourage patients to seek help prior to the onset of future depressive syndromes; review",
"      <strong>",
"      </strong>",
"      symptoms of depression so the patient can identify future episodes of depression; and review treatment options. The clinician should leave the door open to future work with the patient, if this is possible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1394899\">",
"    <span class=\"h1\">",
"     OTHER RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional resources that are available to learn more about using IPT include treatment manuals and a professional organization. Both a comprehensive and an abbreviated manual are available to help deliver treatment in a standardized (consistent) manner [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/2,40\">",
"     2,40",
"    </a>",
"    ]. The comprehensive manual has been translated into multiple languages, including French, German, Italian, Japanese, and Spanish [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4425/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The International Society for Interpersonal Psychotherapy is an organization that enables researchers and clinicians to share information about IPT. The society organizes conferences and provides current information about international training opportunities in IPT (",
"    <a class=\"external\" href=\"file://www.interpersonalpsychotherapy.org/\">",
"     file://www.interpersonalpsychotherapy.org/",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1395047\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interpersonal Psychotherapy (IPT) is a time-limited psychotherapy for treating depression. The treatment focuses upon improving problematic interpersonal relationships or circumstances that are directly related to the current depressive episode. (See",
"      <a class=\"local\" href=\"#H72107712\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several therapeutic procedures are used throughout IPT, including psychoeducation that major depression is a treatable medical illness that is not the patient&rsquo;s fault, and that current, upsetting life events trigger depressive episodes in vulnerable patients. The clinician also develops a strong therapeutic alliance, encourages patients to express emotions, and focuses upon specifics. In addition, self-report, standardized rating scales are regularly completed by the patient. Some severely ill patients may require both IPT and pharmacotherapy. (See",
"      <a class=\"local\" href=\"#H1633421\">",
"       'Therapeutic strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IPT is divided into three phases: initial, middle, and termination. &nbsp;Each phase has specific goals and tasks, and a predetermined duration. (See",
"      <a class=\"local\" href=\"#H6145212\">",
"       'Stages of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial phase of IPT lasts up to three sessions. The different tasks completed in this phase are centered on selecting an interpersonal problem area as the focus of treatment. Problem areas include grief (complicated bereavement), role disputes (different expectations about roles), role transitions (major change in the patient&rsquo;s life circumstances), and interpersonal deficits (social isolation).",
"     </li>",
"     <li>",
"      The components of the initial phase include diagnosing major depression, giving the patient the sick role, taking an interpersonal inventory, establishing a depression timeline, selecting an interpersonal problem area and formulating the case, providing hope, and discussing the treatment contract. (See",
"      <a class=\"local\" href=\"#H72107807\">",
"       'Initial phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The middle phase consists of sessions 4 to 13, during which the clinician and patient work to resolve the selected interpersonal problem area chosen as the treatment focus. Some interventions are specific for a given problem area, whereas other procedures may be used for any problem area. (See",
"      <a class=\"local\" href=\"#H72107857\">",
"       'Middle phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For grief, the clinician facilitates the mourning process by asking about the circumstances around the death and the patient&rsquo;s relationship with the deceased. The patient is also encouraged to reestablish interest in other people and activities. For a role dispute, the clinician identifies the specifics of the dispute and the different expectations in the relationships. Better communication is emphasized if the two parties are negotiating with each other; if the two parties are ready to end the relationship, the patient mourns the loss and focuses on new relationships and activities. For a role transition, the patient mourns losing the old role and masters the skills needed for the new role. For interpersonal deficits, IPT uses past relationships as models for new relationships. (See",
"      <a class=\"local\" href=\"#H21429062\">",
"       'Grief (complicated bereavement)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21429079\">",
"       'Role dispute'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21429087\">",
"       'Role transition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21429095\">",
"       'Interpersonal deficits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interventions that can be used for any of the four interpersonal problem areas include psychoeducation, communication analysis, role play, exploration of options and decision analysis, and socialization and pleasurable activities. (See",
"      <a class=\"local\" href=\"#H10707367\">",
"       'Interventions for any interpersonal problem area'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Termination comprises the final two to four sessions. The patient&rsquo;s interpersonal gains and symptomatic improvement are reviewed, the link between current life events and depression is revisited, and options for any remaining treatment needs are discussed, including maintenance IPT. In addition, the clinician provides psychoeducation about the risk of recurrence and the patient plans future treatment if the need arises. (See",
"      <a class=\"local\" href=\"#H72107866\">",
"       'Termination'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Klerman, GL, Weissman, MM, Rounsaville, BJ, Chevron, ES. Interpersonal Psychotherapy of Depression, Basic Books, New York 1984.",
"    </li>",
"    <li>",
"     Weissman, MM, Markowitz, JC, Klerman, GL. Comprehensive Guide to Interpersonal Psychotherapy, Basic Books, New York 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/3\">",
"      Brown GW, Harris TO, Peto J. Life events and psychiatric disorders. 2. Nature of causal link. Psychol Med 1973; 3:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/4\">",
"      Coyne JC. Depression and the response of others. J Abnorm Psychol 1976; 85:186.",
"     </a>",
"    </li>",
"    <li>",
"     Brown, GW, Harris, T. Social origins of depression: A study of psychiatric disorders in women, Free Press, New York 1978.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/6\">",
"      Henderson S, Byrne G, Duncan-Jones P, et al. Social relationships, adversity and neurosis: a study of associations in a general population sample. Br J Psychiatry 1980; 136:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/7\">",
"      Weissman MM, Klerman GL, Paykel ES, et al. Treatment effects on the social adjustment of depressed patients. Arch Gen Psychiatry 1974; 30:771.",
"     </a>",
"    </li>",
"    <li>",
"     Markowitz, JC, Weissman, MM. Applications of individual interpersonal psychotherapy to specific disorders: Efficacy and indications. In: Textbook of Psychotherapeutic Treatments, Gabbard, GO (Eds), American Psychiatric Publishing, Inc, Washington, DC 2009. p.339.",
"    </li>",
"    <li>",
"     Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition  www.psych.org/guidelines/mdd2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/10\">",
"      Brody AL, Saxena S, Stoessel P, et al. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry 2001; 58:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/11\">",
"      Martin SD, Martin E, Rai SS, et al. Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. Arch Gen Psychiatry 2001; 58:641.",
"     </a>",
"    </li>",
"    <li>",
"     Depression: the treatment and management of depression in adults (update). www.NICE.org.UK/CG90 (Accessed on October 12, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/13\">",
"      American Psychiatric Association. Practice Guideline for the treatment of patients with major depressive disorder, third edition. Am J Psychiatry 2010; 167:1.",
"     </a>",
"    </li>",
"    <li>",
"     Swartz, HA, Markowitz, JC. Techniques of individual interpersonal psychotherapy. In: Textbook of Psychotherapeutice Treatments, Gabbard, GO (Eds), American Psychiatric Publishing, Inc., Washington, DC 2009. p.309.",
"    </li>",
"    <li>",
"     Markowitz, JC. Interpersonal psychotherapy. In: The American Psychiatric Publishing Textbook of Psychiatry, Fifth Edition, Hales, RE, Yudofsky, SC, Gabbard, GO (Eds), American Psychiatric Publishing, Washington, DC 2008. p.1191.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/16\">",
"      Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/17\">",
"      Kroenke, K, Spitzer, RL. The PHQ-9: a new depression and diagnostic severity measure. Psychiatric Annals 2002; 32:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/18\">",
"      Zimmerman M, Chelminski I, McGlinchey JB, Posternak MA. A clinically useful depression outcome scale. Compr Psychiatry 2008; 49:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/19\">",
"      Zimmerman M, Posternak MA, Chelminski I. Using a self-report depression scale to identify remission in depressed outpatients. Am J Psychiatry 2004; 161:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/20\">",
"      Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/21\">",
"      Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004; 34:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/22\">",
"      Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/23\">",
"      DiMascio A, Weissman MM, Prusoff BA, et al. Differential symptom reduction by drugs and psychotherapy in acute depression. Arch Gen Psychiatry 1979; 36:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/24\">",
"      Reynolds CF 3rd, Frank E, Perel JM, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA 1999; 281:39.",
"     </a>",
"    </li>",
"    <li>",
"     Wilfley, DE, MacKenzie, RK, Welch, RR, et, al. Interpersonal Psychotherapy for Group, Basic Books, New York 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/26\">",
"      Swartz HA, Frank E, Shear MK, et al. A pilot study of brief interpersonal psychotherapy for depression among women. Psychiatr Serv 2004; 55:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/27\">",
"      Swartz HA, Frank E, Zuckoff A, et al. Brief interpersonal psychotherapy for depressed mothers whose children are receiving psychiatric treatment. Am J Psychiatry 2008; 165:1155.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text revision, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     The World Health Organization International Classification of Diseases, ICD-10 Online, Current Version (2007)",
"",
" file://www.who.int/classifications/icd/en/ (Accessed on October 22, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/30\">",
"      PARSONS T. Illness and the role of the physician: a sociological perspective. Am J Orthopsychiatry 1951; 21:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/31\">",
"      Joiner TE Jr, Cook JM, Hersen M, Gordon KH. Double depression in older adult psychiatric outpatients: hopelessness as a defining feature. J Affect Disord 2007; 101:235.",
"     </a>",
"    </li>",
"    <li>",
"     Markowitz, JC, Swartz, HA. Case formulation in interpersonal psychotherapy of depression. In: Handbook of Psychotherapy Case Formulation, 2nd ed, Eels, TE (Eds), Gulford Press, New York 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/33\">",
"      Joiner TE Jr, Steer RA, Abramson LY, et al. Hopelessness depression as a distinct dimension of depressive symptoms among clinical and non-clinical samples. Behav Res Ther 2001; 39:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/34\">",
"      Frank E, Kupfer DJ, Wagner EF, et al. Efficacy of interpersonal psychotherapy as a maintenance treatment of recurrent depression. Contributing factors. Arch Gen Psychiatry 1991; 48:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/35\">",
"      Markowitz JC. The future of interpersonal psychotherapy. J Psychother Pract Res 1997; 6:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/36\">",
"      Foley, SH, Rounsaville, BJ, Weissman, MM, et, al. Individual versus conjoint interpersonal psychotherapy for depressed patients with marital disputes. Int J Fam Psychiatr 1989; 10:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/37\">",
"      Kendler KS, Gatz M, Gardner CO, Pedersen NL. A Swedish national twin study of lifetime major depression. Am J Psychiatry 2006; 163:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/38\">",
"      Jacobson, NS, Martell, CR, Dimidjian, S. Behavioral activation treatment for depression: Returning to contextual roots. Clin Psychol Sci Prac 2001; 8:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4425/abstract/39\">",
"      Frank E, Kupfer DJ, Buysse DJ, et al. Randomized trial of weekly, twice-monthly, and monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression. Am J Psychiatry 2007; 164:761.",
"     </a>",
"    </li>",
"    <li>",
"     Weissman, MM, Markowitz, JC, Klerman, GL. Clinician's Quick Guide to Interpersonal Psychotherapy, Oxford University Press, New York 2007.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14680 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-3EAB60D91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_20_4425=[""].join("\n");
var outline_f4_20_4425=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1395047\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H72107712\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1633421\">",
"      THERAPEUTIC STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3946659\">",
"      Principles of IPT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21428866\">",
"      Common therapeutic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H478580\">",
"      Standardized, self-report rating scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H545430\">",
"      Combining IPT with pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6145003\">",
"      DELIVERING INTERPERSONAL PSYCHOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6145110\">",
"      Individual versus group format",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6145154\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6145212\">",
"      Stages of treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H72107807\">",
"      - Initial phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H72107815\">",
"      Diagnose major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H72107822\">",
"      Give the patient the sick role",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H72107829\">",
"      Take an interpersonal inventory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H72107836\">",
"      Establish the depression timeline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H72107843\">",
"      Select interpersonal problem area and formulate the case",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H72107850\">",
"      Provide hope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H546973\">",
"      Discuss treatment contract",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H72107857\">",
"      - Middle phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10707359\">",
"      Interventions for each interpersonal problem area",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H21429062\">",
"      - Grief (complicated bereavement)",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H21429079\">",
"      - Role dispute",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H21429087\">",
"      - Role transition",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H21429095\">",
"      - Interpersonal deficits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10707367\">",
"      Interventions for any interpersonal problem area",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H72107866\">",
"      - Termination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1394899\">",
"      OTHER RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1395047\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14680\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14680|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?25/29/26065\" title=\"form 1\">",
"      CUDOS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14680|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/12/14541\" title=\"table 1\">",
"      PHQ-9 questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/55/27516\" title=\"table 2\">",
"      Techniques of the initial phase of Interpersonal Psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/4/44108\" title=\"table 3\">",
"      Techniques of the middle phase of Interpersonal Psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/41/9884\" title=\"table 4\">",
"      Techniques of termination phase of Interpersonal Psychotherapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28328?source=related_link\">",
"      Depression in adults: Psychodynamic psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17674?source=related_link\">",
"      Interpersonal Psychotherapy (IPT) for depressed adults: Indications, theoretical foundation, general concepts, and efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4745?source=related_link\">",
"      Using scales to monitor symptoms and treatment of depression (measurement based care)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_20_4426="Management of left main coronary artery disease";
var content_f4_20_4426=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of left main coronary artery disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/20/4426/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/20/4426/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/20/4426/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/20/4426/contributors\">",
"     Gabriel S Aldea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/20/4426/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/20/4426/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/20/4426/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant, defined as a greater than 50 percent narrowing, left main coronary artery disease (LMCAD) is found in 4 to 6 percent of all patients who undergo coronary arteriography [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/1\">",
"     1",
"    </a>",
"    ]. When present, it is associated with multivessel coronary artery disease (MVCAD) about 70 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients are symptomatic and at high risk of cardiovascular events, since occlusion of this vessel compromises flow to at least 75 percent of the left ventricle, unless it is protected by collateral flow or a patent bypass graft to either the left anterior descending or circumflex artery. Studies performed before revascularization with coronary artery bypass graft surgery (CABG) became the standard of care revealed a poor prognosis for these patients, with three-year survival as low as 37 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/4\">",
"     4",
"    </a>",
"    ]. CABG, when directly compared to medical therapy, is associated with significantly better cardiovascular outcomes, including mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Percutaneous coronary intervention (PCI) with stenting has generally been restricted to such patients considered inoperable or at high risk for CABG, or with prior CABG and at least one patent graft to the left anterior descending or circumflex artery (so-called \"protected\" left main disease). Graft patency is important in this setting in the event of acute or late closure after PCI. However, evidence is increasing to support the use of PCI with stenting in some cases. (See",
"    <a class=\"local\" href=\"#H266319044\">",
"     'PCI versus CABG'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Asymptomatic patients with left main lesions felt to not be hemodynamically significant should be managed with preventative therapies. Patients with anginal symptoms attributable to lesions elsewhere should be managed with therapies similar to those used in other patients with coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will discuss most aspects of the management of patients with LMCAD. The approach to patients with multivessel coronary artery disease without LMCAD is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of left main disease is usually made by angiography. However, certain findings on exercise testing or, in patients with acute coronary syndromes on the ECG, are suggestive of left main disease. These include diffuse and severe ST-segment deviation or significant ventricular arrhythmias on ECG monitoring or hypotension during exercise.",
"   </p>",
"   <p>",
"    Among patients with stable angina, exercise testing demonstrating early or pronounced ischemic ECG changes in stage I or II of the Bruce protocol or at heart rates less than 120",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    or a high risk Duke treadmill score, can identify patients who are more likely to have left main coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H2#H2\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Adverse predictors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H11#H11\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Duke treadmill score'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A left main pattern on exercise thallium testing is characterized by reduced thallium uptake in the septum and anterior and lateral walls or evidence of generalized ischemia (increased lung uptake or decline in ejection fraction). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link&amp;anchor=H16#H16\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\", section on 'Left main coronary artery disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with left main disease should receive preventative therapies known to decrease the risk of cardiovascular events, such as smoking cessation, achieving target blood pressure goals, lipid lowering therapy with statins, and proper management of diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CABG VERSUS MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies comparing CABG to medical therapy were initially obtained in patients with left main disease and stable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/6\">",
"     6",
"    </a>",
"    ] and led to strong guideline recommendations for CABG in patients with varied presentations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H266319044\">",
"     'PCI versus CABG'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=see_link&amp;anchor=H6#H6\">",
"     \"Medical therapy versus revascularization in the management of stable angina pectoris\", section on 'Effects on survival'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Significant left main disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of controlled trials and one registry have shown that patients with more than 50 percent left main coronary artery stenosis benefit from revascularization with CABG compared with medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/6,8-12\">",
"     6,8-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Veterans Administration Cooperative Study that compared a strategy of initial CABG versus deferred CABG, there was a substantial survival advantage for patients assigned to initial CABG at two years (93 versus 71 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/8,9\">",
"     8,9",
"    </a>",
"    ] and at 11 years, but not at 18 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/10\">",
"     10",
"    </a>",
"    ]. The benefit was greatest in high-risk patients with &gt;75 percent left main stenosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    left ventricular dysfunction; there was a nonsignificant trend toward benefit in patients with 50 to 75 percent stenosis and normal left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CASS registry demonstrated similar results. Patients with left main disease were divided into risk categories depending upon the severity of the stenosis and left ventricular function. At three years in the risk categories with the best and worst prognosis, survival was improved with surgery (97 versus 85 and 82 versus 34 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/11\">",
"     11",
"    </a>",
"    ]. At 15 years, there were increases in both overall survival and median survival with CABG compared to medical therapy (37 versus 27 percent and 13.3 versus 6.6 years, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/12\">",
"     12",
"    </a>",
"    ]. Furthermore, 25 percent of patients in the medical group ultimately underwent CABG.",
"   </p>",
"   <p>",
"    In the CASS study, the survival benefit was not observed at either 3 or 15 years in certain subgroups: those with mild left main stenosis (50 to 59 percent); and those with a non-stenotic dominant right coronary artery with normal or mildly reduced left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. By comparison, there was a nonsignificant trend toward a better outcome with CABG in these two subgroups in the Veterans Administration Cooperative Study [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcomes of patients with left main disease treated with CABG have improved over time. Reports of those who underwent CABG after 1995 suggest that the 30-day mortality ranges between 3 and 4.2 percent and the survival at two years is approximately 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Left main equivalent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left main equivalent disease, defined as severe (&ge;70 percent) proximal left anterior descending and proximal left circumflex disease, appears to behave similarly to true left main disease, although the prognosis is somewhat better [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/13\">",
"     13",
"    </a>",
"    ]. The largest experience with such patients comes from the CASS registry of 912 patients with left main equivalent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/14\">",
"     14",
"    </a>",
"    ]. At more than 16-year follow-up, CABG was associated with significant increases in mean survival (13.1 versus 6.2 years) and the likelihood of survival (44 versus 31 percent); 26 percent of medically treated patients ultimately underwent CABG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Indeterminate disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients have \"indeterminate\" left main disease. This term is used when left main lesion severity is difficult to quantify by angiography but appears to be approximately 50 percent. In such patients the decision between CABG and medical therapy is difficult. Adjunctive testing with either fractional flow reserve (FFR) or intracoronary ultrasonography (IVUS) has been used to guide therapy in such patients.",
"   </p>",
"   <p>",
"    The following findings have been noted in observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 213 patients with angiographically equivocal left main coronary artery stenosis, 138 with an FFR &ge;0.80 were treated medically (or another stenosis was treated with PCI) and 75 with an FFR &lt;0.80 were treated with CABG [",
"      <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/15\">",
"       15",
"      </a>",
"      ]. The five-year survival estimates were not significantly different between the two groups (90 and 85 percent, respectively). There was only moderate correlation with a large scatter between FFR and percent diameter stenosis determined by quantitative coronary angiography. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13672?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical use of coronary artery pressure and Doppler flow measurements\", section on 'Intermediate severity stenosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a series of 121 patients with angiographically normal left main coronary arteries, the lower range of normal left main minimum luminal area (MLA) was 7.5 mm",
"      <sup>",
"       2",
"      </sup>",
"      using IVUS [",
"      <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/16\">",
"       16",
"      </a>",
"      ]. Using this information, IVUS was performed on 214 patients with indeterminate left main lesions. Left main revascularization, mostly using CABG, was performed in the majority of the 83 patients with an MLA &lt;7.5 mm",
"      <sup>",
"       2",
"      </sup>",
"      , but was deferred in the majority of the 131 patients with an MLA &ge;7.5 mm",
"      <sup>",
"       2",
"      </sup>",
"      . At a mean follow-up of 3.3 years, there was no significant difference in major adverse cardiac events (target vessel revascularization [TVR], MI, or death). This study was not designed to address the question of whether all left main stenoses with an MLA &lt;7.5 mm",
"      <sup>",
"       2",
"      </sup>",
"      require revascularization. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34234?source=see_link\">",
"       \"Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a prospective study of 354 patients with LMCAD who underwent IVUS, revascularization was deferred in 96 percent if the MLA was &ge;6 mm",
"      <sup>",
"       2",
"      </sup>",
"      and performed in 91 percent if the MLA was &lt;6 mm",
"      <sup>",
"       2",
"      </sup>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/17\">",
"       17",
"      </a>",
"      ]. After two year follow-up, cardiac death-free survival was not significantly different between the two groups (98 percent and 95 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend either IVUS or FFR assessment to assist in the decision for CABG in patients with indeterminate disease. We believe these observational studies show that assessment may define a group for whom deferring surgery does not lead to worse outcomes.",
"   </p>",
"   <p>",
"    The optimal approach to patients with less than 50 percent left main stenosis is uncertain. One study evaluated 122 patients with symptomatic left main disease who had an \"ambiguous\" angiogram and did not undergo revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/18\">",
"     18",
"    </a>",
"    ]. There was a moderate correlation between intracoronary ultrasound (IVUS) and quantitative coronary angiography in assessing reference diameter but a poor correlation in assessing minimum lumen diameter (MLD). After a mean follow-up of almost one year, the rate of cardiac events in patients without revascularization was only 14 percent. IVUS MLD was the most important predictor of events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266319044\">",
"    <span class=\"h1\">",
"     PCI VERSUS CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;CABG has a long track record of safety and efficacy in patients with LMCAD. The application of percutaneous coronary intervention (PCI), usually with stenting, to the left main coronary artery began in patients who were not candidates for CABG. Observational studies and randomized trials suggested equivalent outcomes with these two forms of revascularization in some patients with LMCAD.",
"   </p>",
"   <p>",
"    The observational studies above suggest, but do not prove, that percutaneous coronary intervention (PCI) with stenting may be an option to coronary artery bypass graft surgery (CABG) for patients with unprotected LMCAD. Several nonrandomized studies and a few randomized trials have compared these two forms of revascularization and found, not surprisingly, that CABG is associated with a higher incidence of adverse in-hospital outcomes, including death, myocardial infarction (MI), and stroke. During intermediate and longer term follow-up, outcomes of death or MI are similar for bypass surgery and stenting, while repeat revascularization rates are significantly higher for coronary stenting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266319229\">",
"    <span class=\"h2\">",
"     PRECOMBAT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PRECOMBAT trial randomly assigned 600 patients with unprotected LMCAD to PCI with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -eluting stents or CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/19\">",
"     19",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary end point of major adverse cardiac or cerebrovascular events (death from any cause, MI, stroke, or ischemia-driven target vessel revascularization) at one year met the criteria for non-inferiority of PCI. The event rates were 8.7 and 6.7 percent for PCI and CABG (absolute risk difference 2.0, 95% CI -1.6 to 5.6, respectively) and the difference was attributable to the expected higher rate of ischemia-driven target lesion revascularization in the PCI group (6.1 versus 3.4 percent). The two groups had similar rates of the other individual components of the composite.",
"     </li>",
"     <li>",
"      At two years, the event rates for the primary outcome were still higher but not significantly different with PCI (12.2 versus 8.1 percent with CABG). The difference between the two groups was due to a statistically significant higher rate of ischemia-driven target lesion revascularization with PCI (9.0 and 4.2 percent). The rates of stroke did not differ significantly (0.4 versus 0.7 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a subgroup analysis of the primary endpoint, there was a trend toward a better outcome with PCI in patients with left main-only disease, while patients with triple-vessel disease appeared to do better with CABG. The hazard ratios (HR) and confidence intervals (CI) by subgroup were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left main only: HR 0.39, 95% CI 0.04-3.72",
"     </li>",
"     <li>",
"      Left main with single-vessel disease: 0.70, 95% CI 0.11-4.16",
"     </li>",
"     <li>",
"      Left main with double-vessel disease: 1.04, 95% CI 0.47-2.32",
"     </li>",
"     <li>",
"      Left main with triple-vessel disease: 3.05, 95% CI 1.29-7.21",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interestingly this finding was not observed patients were evaluated by SYNTAX score. This discrepancy between the number of associated diseased vessels and the SYNTAX score is an unexpected finding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=see_link&amp;anchor=H17#H17\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'SYNTAX trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limitations of PRECOMBAT include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower than expected event rates, which makes us less confident in the finding of noninferiority",
"     </li>",
"     <li>",
"      The systematic performance of repeat angiography in the PCI group, which may have led to a greater number of cases of ischemia-driven target lesion revascularization that might not have been detected clinically.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266319236\">",
"    <span class=\"h2\">",
"     SYNTAX trial subgroup analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subgroup analysis of the SYNTAX trial, which randomly assigned 1800 patients with multivessel or left main CAD to either stenting with a paclitaxel-eluting stent or CABG, evaluated outcomes in the 705 patients with LMCAD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/20\">",
"     20",
"    </a>",
"    ]. Among patients with LMCAD, 35 percent had LMCAD alone or associated with single vessel disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=see_link&amp;anchor=H17#H17\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'SYNTAX trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary outcome (the 12-month rate of major adverse cardiac or cerebrovascular events [death from any cause, stroke, MI, or repeat revascularization]) was not significantly different in the PCI and CABG groups (15.8 versus 13.7). Patients with PCI had a significantly higher rate of repeat revascularization (11.8 versus 6.5 percent), as seen in PRECOMBAT, and a significantly lower rate of stroke (0.3 versus 2.7 percent).",
"   </p>",
"   <p>",
"    Outcomes according to the complexity of disease were evaluated and the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of the primary outcome with PCI increased significantly as the number of vessels with associated disease increased (7.1, 7.5, 19.8, and 19.3 percent for 0, 1, 2, and 3 vessel associated disease, respectively). The comparable rates for CABG patients were 8.5, 13.2, 14.4, and 15.4 percent, respectively.",
"     </li>",
"     <li>",
"      When grouped according to the SYNTAX score (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=see_link&amp;anchor=H17#H17\">",
"       \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'SYNTAX trial'",
"      </a>",
"      ), patients with low (&lt;23) or intermediate (23-32) scores did not differ significantly with respect to the primary outcome comparing PCI with CABG. However, those with high (&gt;32) scores had a significantly higher rate of the primary outcome with PCI (25.3 versus 12.9 percent). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Five-year outcomes of SYNTAX have been reported and are consistent with the findings at 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/21\">",
"     21",
"    </a>",
"    ]. For patients with SYNTAX scores of 0 to 22 and 23 to 32, outcomes between PCI and CABG were similar if unprotected left main disease was present (30.4 versus 31.5 and 32.7 and 32.3 percent, respectively). However, for patients with a SYNTAX score &ge;33, the primary composite outcome occurred more frequently in patients randomized to PCI (46.5 versus 29.7, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266319243\">",
"    <span class=\"h2\">",
"     Observational studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several observational studies, with follow-up between 30 days and 3.5 years, have compared drug-eluting stents (DES) to CABG for patients with LMCAD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. For example, in the DELTA multicenter registry, 1874 patients with unprotected LMCAD treated with PCI using first generation drug-eluting stents were compared to 901 with CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/26\">",
"     26",
"    </a>",
"    ]. At a median follow-up of approximately 3.5 years, there was no difference in the primary composite end point of death, cerebrovascular accidents, and MI (17.6 versus 16.9 percent, respectively; adjusted hazard ratio 1.11, 96% CI 0.85-1.42). Similar to other studies, the rate of target vessel revascularization was higher in the PCI group (15.5 versus 5.2 percent, respectively).",
"   </p>",
"   <p>",
"    Five-year outcomes, according to the complexity of coronary artery disease, were evaluated in a report of 1146 patients with LMCAD in the MAIN-COMPARE registry who received either CABG (n = 501) or either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    or paclitaxel-eluting stents (n = 645) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/27\">",
"     27",
"    </a>",
"    ]. The complexity of associated disease was measured using the SYNTAX score: a low-risk score was defined as &le;22, an intermediate-risk score as 23-32, and a high-risk score as &ge;33. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=see_link&amp;anchor=H17#H17\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'SYNTAX trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings were noted after multivariate adjustment at a median follow-up of 55 months:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Comparing DES with CABG in patients with a low-risk SYNTAX score, the rates of death (6.1 versus 16.2; HR 0.52. 95% CI 0.21-1.28) and the composite of death, Q-wave MI, or stroke (6.4 for versus 16.2 percent; HR 0.54, 95% CI 0.22-1.34) favored DES but were not statistically significant.",
"     </li>",
"     <li>",
"      Comparing DES with CABG in patients with high-risk SYNTAX scores, the rates of death (26.9 versus 17.8; HR 1.46, 95% CI 0.92-2.3) and the composite (27.6 versus 19.5 percent; HR 1.26, 95% CI 0.87-2.12) favored CABG but were not statistically significant.",
"     </li>",
"     <li>",
"      In patients with intermediate SYNTAX scores, the safety outcomes were similar in the two groups.",
"     </li>",
"     <li>",
"      Target vessel revascularization occurred significantly more often in patients who received DES, irrespective of SYNTAX score.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these observational studies generally support the findings of the randomized trials discussed above, they provide longer follow-up and have the potential advantage of observing outcomes in real world patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6763783\">",
"    <span class=\"h2\">",
"     Meta-analysis of DES versus CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2012 meta-analysis evaluated outcomes in over 5000 patients in nine observational studies and three randomized trials who received either a DES or CABG for unprotected LMCAD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/28\">",
"     28",
"    </a>",
"    ]. At one-year follow-up, there were trends toward lower risk of death (odds ratio [OR] 0.68, 95% CI 0.45-1.02) and the composite of death, MI or stroke (OR 0.70, 85% CI 0.49-1.00 in the DES group). The need for target vessel revascularization was higher in the DES group (OR 3.52, 95% CI 2.72-4.56). This meta-analysis is limited in terms of generalizability due to the heterogeneity of the studies, relatively short follow-up, and the use of predominantly first generation DES. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16360?source=see_link\">",
"     \"Comparison of drug-eluting intracoronary stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266319250\">",
"    <span class=\"h2\">",
"     Summary of evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;We arrive at the following conclusions regarding the evidence comparing CABG to PCI with stenting for patients with LMCAD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At one year and longer, CABG and PCI appear to have similar rates of the combined end point of death from any cause, MI, stroke.",
"     </li>",
"     <li>",
"      As the complexity of associated coronary artery disease increases, assessed either by the SYNTAX score or as the number of vessels that need revascularization, the benefit in favor of CABG over PCI with stenting increases.",
"      <br/>",
"      <br/>",
"      For patients with lower complexity coronary disease who can undergo PCI at an acceptable risk and with reasonable probability for success, PCI may be an acceptable or even preferred option. Until more data are available to validate this approach, however, our experts believe that CABG should remain the preferred option.",
"      <br/>",
"      <br/>",
"      CABG is associated with a significantly higher incidence of adverse in-hospital outcomes, including death, MI, and stroke. However, the long-term rates of death, MI, and stroke are comparable.",
"     </li>",
"     <li>",
"      PCI with stenting is associated with a higher incidence of target vessel revascularization at long-term follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If left main PCI is being considered, it should not be performed immediately after coronary arteriography. The patient should hear opinions from a multidisciplinary team prior to deciding on a revascularization strategy. (See",
"    <a class=\"local\" href=\"#H266319516\">",
"     'Major society guidelines'",
"    </a>",
"    below.) Exceptions to this principle include patients who are unstable and need immediate revascularization in the catheterization laboratory or those in whom CABG is not an option for any reason.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266319516\">",
"    <span class=\"h2\">",
"     Major society guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2011 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Society",
"    </span>",
"    for Cardiovascular Angiography and Interventions PCI guideline makes a strong recommendation for CABG in LMCAD patients with significant (&gt;50 percent diameter stenosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/29\">",
"     29",
"    </a>",
"    ]. A weaker recommendation is made for PCI as an alternative to CABG in these patients if anatomic conditions associated with a low risk of PCI procedural complication are present and a good long-term outcome is expected, as well as the presence of clinical characteristics that predict a significantly increased risk of adverse CABG related outcomes.",
"   </p>",
"   <p>",
"    Guidelines on myocardial revascularization were published by the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/30\">",
"     30",
"    </a>",
"    ]. CABG was preferred to PCI in all anatomic or SYNTAX score subgroups, except for the patient with one or two disease without involvement of the proximal left anterior descending artery. PCI was felt to be contraindicated in patients with associated three vessel disease who had either a SYNTAX score &gt;22 or a high likelihood of incomplete revascularization with PCI as well as in patients with two or three vessel disease and a SYNTAX score &ge;33. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=see_link&amp;anchor=H17#H17\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials\", section on 'SYNTAX trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the 2010 European guidelines on myocardial revascularization, which strongly suggest that the patient should consider opinions from a multidisciplinary team (including both an interventional cardiologist and a cardiothoracic surgeon at a minimum) prior to deciding upon a revascularization strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recognizing the diversity of clinical and anatomic scenarios in patients with stable disease, this document emphasizes the importance of considering the specific scenario, as well as a patient&rsquo;s preferences, in the process of decision making.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266319667\">",
"    <span class=\"h1\">",
"     PCI WITH STENTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The application of percutaneous coronary intervention (PCI), usually with stenting, to the left main coronary artery began in patients who were not candidates for CABG. Observations of short term safety and efficacy led to a wider use of PCI. This section will present evidence related to the performance of PCI in these patients.",
"   </p>",
"   <p>",
"    The use of PCI in patients with protected lesions is discussed below. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Protected lesions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2733901\">",
"    <span class=\"h2\">",
"     DES versus BMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is high quality evidence of a lower rate of target vessel revascularization using drug-eluting (DES) compared to bare metal (BMS) stents in patients with unprotected LMCAD. For those patients who can comply with a recommendation for long-term dual antiplatelet therapy, we recommend DES as opposed to BMS.",
"   </p>",
"   <p>",
"    Most initial observational reports documented a higher frequency of procedural success as well as less late lumen loss and lower rates of angiographic restenosis and target vessel revascularization (TVR) with DES [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. In the only randomized comparison of DES and BMS for the treatment of unprotected LMCAD, 103 patients with stable angina were assigned to receive either a paclitaxel-eluting stent (PES) or BMS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/35\">",
"     35",
"    </a>",
"    ]. There were no in-hospital deaths and 75 percent of the patients had involvement of the distal bifurcation. At six month angiographic and clinical follow-up, there was a statistically significant reduction in the binary restenosis rate with PES (6 versus 22 percent), as well as a significant improvement in the major adverse cardiac event-free survival (no death, MI, or TVR; 87 versus 70 percent) that was entirely due to a reduction in TVR (2 versus 16 percent).",
"   </p>",
"   <p>",
"    Similar findings were noted in the MAIN-COMPARE and LE MANS registries, which enrolled patients with unprotected LMCAD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. MAIN-COMPARE, the larger of these two (n = 1217), found no significant difference between patients receiving DES and BMS in the adjusted risk of death or MI (14.3 versus 14.9 percent, respectively) after three years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/36\">",
"     36",
"    </a>",
"    ]. However, TVR at three years was significantly less common with DES (5.4 versus 12.1 percent; hazard ratio 0.40, 95% CI 0.22-0.73), irrespective of whether the treated lesion was at the left main bifurcation or not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2733923\">",
"    <span class=\"h2\">",
"     Comparisons of DES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is an increasing literature comparing one DES to another in a variety of clinical settings (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16360?source=see_link\">",
"     \"Comparison of drug-eluting intracoronary stents\"",
"    </a>",
"    ), there are few studies that have compared DES in patients with LMCAD.",
"   </p>",
"   <p>",
"    Evidence from a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/38\">",
"     38",
"    </a>",
"    ] and several observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/39,40\">",
"     39,40",
"    </a>",
"    ] suggests that outcomes are similar with the paclitaxel- and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -eluting stents (PES and SES, respectively) in patients with left main disease. The randomized trial included 607 patients who were assigned to either an SES or PES [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/38\">",
"     38",
"    </a>",
"    ]. The cumulative incidence of death, MI, or target lesion revascularization at one year was not significantly different between the two stent types (15.8 versus 13.6, SES versus PES).",
"   </p>",
"   <p>",
"    In the ULMD Florence registry of patients with unprotected LMCAD, 224 underwent PCI with a PES and 166 with an everolimus-eluting stent (EES). Among 166 propensity matched pairs, the rate of the primary outcome (cardiac death, nonfatal MI, target vessel revascularization, and stroke) was significantly higher with PES (20.4 versus 10.2 percent; p = 0.010).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2733973\">",
"    <span class=\"h2\">",
"     Distal versus ostial or midshaft lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distal left main is involved in the majority of cases (60 to 94 percent of lesions) and the results of PCI for these patients are worse than for those patients with lesions located at the ostium or mid-shaft [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/41\">",
"     41",
"    </a>",
"    ]. While the overall rate of restenosis is low after stenting for left main disease, the distal left main is the usual site of restenosis and the circumflex ostium is especially vulnerable to recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/42\">",
"     42",
"    </a>",
"    ]. The rate of target lesion revascularization is quite low (less than 5 percent) with single stent approaches to distal left main bifurcation lesions or with drug-eluting stents for ostial or mid-left main lesions.",
"   </p>",
"   <p>",
"    The results are poorer when distal left main bifurcation lesions are treated by a two-stent approach (ie, crush or kissing stents) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/41\">",
"     41",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link\">",
"     \"Use of intracoronary stents for specific coronary lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link&amp;anchor=H14#H14\">",
"     \"Use of intracoronary stents for specific coronary lesions\", section on 'Main versus main plus side branch stenting'",
"    </a>",
"    ). In these patients, the rate of TLR (mostly by repeat catheter-based intervention) may be as high as 25 percent. In the three large case series cited above, for example, restenosis was essentially confined to distal lesions, the majority of which had been treated with stents in both branches [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/32-34,42\">",
"     32-34,42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H152158609\">",
"     'Stenting technique for distal left main lesions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The outcome in distal disease has been evaluated in multiple studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/41,43-45\">",
"     41,43-45",
"    </a>",
"    ]. The following are representative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study evaluated 130 patients from the RESEARCH and T-SEARCH registries who received a DES for left main stenosis; 94 had distal disease and were at higher surgical risk and had a greater extent of coronary artery disease than those without distal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/43\">",
"       43",
"      </a>",
"      ]. At a median follow-up of 19 months, the patients with distal disease had a higher rate of TVR (13 versus 3 percent) and of death or MI (17 versus 8 percent). The technique of stent deployment (two stent techniques or main vessel stenting with balloon rescue of the side branch) failed to predict outcome.",
"     </li>",
"     <li>",
"      The Left Main Taxus registry evaluated outcomes after paclitaxel-eluting stent placement in 291 patients, 78 percent of whom had distal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/44\">",
"       44",
"      </a>",
"      ]. Provisional side branch T stenting was performed in 92 percent of the patients with distal disease and the side branch was stented in 43 percent. Angiographic success was obtained in 99.7 percent. At two year follow-up, TLR was performed in 8.9 percent and the cardiac mortality rate was 5.4 percent.",
"     </li>",
"     <li>",
"      The j-Cypher registry compared outcomes in 380 patients with bifurcation lesions to 96 patients with",
"      <span class=\"nowrap\">",
"       ostial/shaft",
"      </span>",
"      lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/41\">",
"       41",
"      </a>",
"      ]. At three years, patients with bifurcation lesions had a significantly higher rate of TLR (17.1 versus 3.6 percent) and a similar rate of cardiac death (7.9 versus 9.8 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data are limited regarding outcomes with PCI in patients who do not require stenting of the distal left main coronary artery, in part because this site is involved in the majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/42,46\">",
"     42,46",
"    </a>",
"    ]. One observational study reported the following outcomes after placement of a DES in 146 patients who had left main lesions involving the ostium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the mid-shaft (non-bifurcation) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In hospital, there were no cardiac deaths (one non-cardiac death), no Q-wave MIs, and five non-Q-wave MIs (3.4 percent).",
"     </li>",
"     <li>",
"      In the 106 patients who underwent angiographic follow-up at four to six months, mean late lumen loss was 0.01 mm and restenosis occurred in only one patient (0.9 percent).",
"     </li>",
"     <li>",
"      At a mean follow-up of 886 days, there were five deaths (3.4 percent cumulative mortality), one target lesion revascularization, and seven (4.7 percent) target vessel revascularizations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152158609\">",
"    <span class=\"h2\">",
"     Stenting technique for distal left main lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal stenting technique for distal left main lesions is not known. In many cases, the best approach may be determined by the specific anatomy. In general, these lesions need to be approached as bifurcation lesions, which generally are technically challenging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link&amp;anchor=H12#H12\">",
"     \"Use of intracoronary stents for specific coronary lesions\", section on 'Bifurcation lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of stenting strategies have been employed. The DKCRUSH-III study randomly assigned 419 patients with unprotected left main distal bifurcation lesions to a double kissing crush or a culotte technique [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/47\">",
"     47",
"    </a>",
"    ]. The primary composite end point (cardiac death, myocardial infarction, and target vessel revascularization at one year) occurred more often in the culotte group (16.3 versus 6.2 percent; p = 0.001), attributable mainly to an increased rate of target vessel revascularization (11.0 versus 4.3 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2734016\">",
"    <span class=\"h2\">",
"     Long-term outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the long-term outcomes of PCI with stenting for unprotected left main lesions are limited, in part because major society guidelines have recommended against PCI for unprotected left main disease. (See",
"    <a class=\"local\" href=\"#H266319516\">",
"     'Major society guidelines'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most of the outcomes with DES presented above were evaluated with two years or less of follow-up. Longer term outcomes from registries are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The DELFT registry evaluated outcomes with DES in 358 \"real world\" patients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/48\">",
"       48",
"      </a>",
"      ]. At a minimum follow-up of three years, cardiac death and reinfarction occurred in 9.2 and 8.6 percent of patients, respectively. The rate of cardiac death was higher in patients treated emergently compared to those treated electively (21.4 versus 6.2 percent).",
"     </li>",
"     <li>",
"      The j-Cypher registry evaluated outcomes in nearly 13,000 patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      -eluting stents (SES), 582 of whom had unprotected LMCAD [",
"      <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/41\">",
"       41",
"      </a>",
"      ]. At three years, there was no significant difference in adjusted mortality between the patients with and without LMCAD (hazard ratio 1.23, 95% CI 0.95-1.60).",
"     </li>",
"     <li>",
"      In the LE MANS registry discussed above, major adverse cardiovascular and cerebral events (MACCE) occurred in 25 percent of patients (death in 14 and target lesion revascularization in 8 percent) during a mean follow-up of 3.8 years [",
"      <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/37\">",
"       37",
"      </a>",
"      ]. The 5- and 10-year survival rates were 78 and 69 percent. The differences between DES and BMS are presented separately. (See",
"      <a class=\"local\" href=\"#H2733901\">",
"       'DES versus BMS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rates of angiographic in-stent restenosis (ISR) vary from 8 to 42 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/49\">",
"       49",
"      </a>",
"      ]. In a large Korean registry of 402 patients who underwent left main stenting with DES and then underwent six month angiographic follow-up, the overall incidence of angiographic ISR was 17.6 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/49\">",
"       49",
"      </a>",
"      ]. Of the patients with ISR, 56 percent underwent repeat PCI, 14 percent underwent coronary artery bypass graft surgery, and 30 percent were treated medically.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66437025\">",
"    <span class=\"h2\">",
"     Adjunctive interventions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66437033\">",
"    <span class=\"h3\">",
"     Circulatory assist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients selected for left main PCI require advanced cardiac support, such as with an intraaortic balloon pump, due to increased risk for hemodynamic compromise during the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13896?source=see_link\">",
"     \"Intraaortic balloon pump counterpulsation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15911?source=see_link\">",
"     \"Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66437040\">",
"    <span class=\"h3\">",
"     Debulking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left main lesions are frequently calcified and debulking with rotational atherectomy has been performed prior to stenting in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41142?source=see_link&amp;anchor=H3#H3\">",
"     \"Specialized revascularization devices in the management of coronary heart disease\", section on 'Rotational atherectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66437047\">",
"    <span class=\"h3\">",
"     Dual antiplatelet therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have undergone PCI for LMCAD must understand the need for prolonged dual antiplatelet therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/23,42\">",
"     23,42",
"    </a>",
"    ]. The issue of high residual platelet reactivity after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    therapy in patients who have received stents for LMCAD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link&amp;anchor=H22#H22\">",
"     \"Nonresponse and resistance to clopidogrel\", section on 'Explanations for clopidogrel treatment failure and resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66437054\">",
"    <span class=\"h3\">",
"     Follow-up angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not recommend routine follow-up with coronary angiography in patients who have undergone left main PCI with DES. While these patients remain at relatively high risk for recurrent events, follow-up angiography does not predict the development of stent thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Protected lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a patent bypass graft to either the left anterior descending or circumflex, who are considered to be \"protected,\" may require left main intervention because of recurrent ischemia. Protected lesions are anatomically similar to those not previously bypassed. However, their physiology during treatment and the consequences of abrupt closure and restenosis are much more forgiving because of continued flow to the protected territory.",
"   </p>",
"   <p>",
"    The outcome of such protected left main interventions is more favorable than when there is no patent graft to the left coronary system (ie, unprotected) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. In essence, stenting in this circumstance is being performed for a single vascular territory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PRIMARY PCI FOR ACUTE MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data on the use of PCI in patients with acute MI due to left main disease. Older small series noted in-hospital mortality rates of 30 to 35 percent following PCI with or without stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Not surprisingly, the outcomes in such patients are worse than in those with left main disease who undergo elective PCI (",
"    <a class=\"graphic graphic_figure graphicRef55972 \" href=\"UTD.htm?2/61/3038\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The cases reported represent a selected group that survived to reach the cardiac catheterization laboratory. More recent (2011) observational studies have reported lower in-hospital mortality rates, ranging from 11 to 21 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More data are available in patients with cardiogenic shock complicating acute MI. In the SHOCK trial registry, 16 percent of patients had significant left main disease (although not necessarily left main occlusion) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/60\">",
"     60",
"    </a>",
"    ]. Although the patients who underwent angiography had a lower baseline risk and better hemodynamic profile than those who did not, mortality in these patients was higher than in those with circumflex, left anterior descending, or right coronary artery lesions (79 versus 37 to 42 percent).",
"   </p>",
"   <p>",
"    The potential efficacy of PCI was illustrated in a report from an observational registry of patients with unprotected left main stenosis; 40 patients with an acute MI (37 of whom had cardiogenic shock) underwent emergency PCI (17 with stenting) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/20/4426/abstract/61\">",
"     61",
"    </a>",
"    ]. The rates of in-hospital death (35 versus 70 percent) and need for bypass surgery (6 versus 22 percent) were lower in those who received a stent compared to primary PTCA alone. Stenting was also associated with a higher survival rate at 12 months (53 versus 35 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with untreated significant left main and left main equivalent coronary artery disease have worse outcomes, including survival, with medical therapy compared to revascularization. We recommend revascularization, as opposed to medical therapy, for patients with left main coronary artery disease (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'CABG versus medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the aggregate, studies of patients with left main coronary artery disease (LMCAD) suggest that the composite outcome of death, MI, and stroke is similar in patients with LMCAD who are treated with coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention (PCI). However, the rate of target vessel revascularization is higher with PCI at one year (and longer). (See",
"      <a class=\"local\" href=\"#H266319044\">",
"       'PCI versus CABG'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      <br/>",
"      Some subgroups of patients with LMCAD are likely to do better with CABG (see",
"      <a class=\"local\" href=\"#H266319044\">",
"       'PCI versus CABG'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Those with associated two or three vessel disease, particularly with those with either high risk scores, such as SYNTAX, or those who are unlikely to be fully revascularized with PCI.",
"     </li>",
"     <li>",
"      Patients with poor left ventricular systolic function, such as those with a left ventricular ejection fraction of less than 30 percent, although these patients were not evaluated in the above randomized trials.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with unprotected left main coronary artery disease who are reasonable surgical candidates:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend CABG, as opposed to PCI, if there is associated three vessel disease or two vessel disease with a high SYNTAX score (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H266319044\">",
"       'PCI versus CABG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest CABG as opposed to PCI in patients with left main only or one or two vessel disease and a low SYNTAX score (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Those patients who have been fully informed of the relative benefits and risk of the two procedures and who have a strong preference to not undergo CABG may reasonably choose PCI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For those patients who undergo PCI with stenting and who can comply with at least 12 months of thienopyridine therapy, we recommend DES in preference to BMS (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2733901\">",
"       'DES versus BMS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases, a thorough discussion of the relative risks and benefits of the two forms of revascularization should take place",
"      <strong>",
"       after",
"      </strong>",
"      coronary angiography between the patient and a healthcare team that involves an interventional cardiologist and a cardiothoracic surgeon at a minimum.",
"      <br/>",
"      <br/>",
"      Patients in whom proceeding directly to PCI after coronary arteriography include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients presenting with acute coronary syndrome who have left main occlusion and who are hemodynamically unstable. Such patients require emergent revascularization, with PCI generally being the most expedient and safe choice. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link&amp;anchor=H37#H37\">",
"       \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\", section on 'PCI versus CABG'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who are not surgical candidates who have been informed of the benefits and risks of PCI before the procedure.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/1\">",
"      Ragosta M, Dee S, Sarembock IJ, et al. Prevalence of unfavorable angiographic characteristics for percutaneous intervention in patients with unprotected left main coronary artery disease. Catheter Cardiovasc Interv 2006; 68:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/2\">",
"      Taggart DP, Kaul S, Boden WE, et al. Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery. J Am Coll Cardiol 2008; 51:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/3\">",
"      Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/4\">",
"      Conley MJ, Ely RL, Kisslo J, et al. The prognostic spectrum of left main stenosis. Circulation 1978; 57:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/5\">",
"      Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/6\">",
"      Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344:563.",
"     </a>",
"    </li>",
"    <li>",
"     Smith, SC Jr, Feldman, TE, Hirshfeld, JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention&mdash;Summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47:e1. Available at: www.acc.org/qualityandscience/clinical/statements.htm (accessed September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/8\">",
"      Murphy ML, Hultgren HN, Detre K, et al. Treatment of chronic stable angina. A preliminary report of survival data of the randomized Veterans Administration cooperative study. N Engl J Med 1977; 297:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/9\">",
"      Takaro T, Peduzzi P, Detre KM, et al. Survival in subgroups of patients with left main coronary artery disease. Veterans Administration Cooperative Study of Surgery for Coronary Arterial Occlusive Disease. Circulation 1982; 66:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/10\">",
"      Eighteen-year follow-up in the Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery for stable angina. The VA Coronary Artery Bypass Surgery Cooperative Study Group. Circulation 1992; 86:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/11\">",
"      Chaitman BR, Fisher LD, Bourassa MG, et al. Effect of coronary bypass surgery on survival patterns in subsets of patients with left main coronary artery disease. Report of the Collaborative Study in Coronary Artery Surgery (CASS). Am J Cardiol 1981; 48:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/12\">",
"      Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical and medical group survival in patients with left main coronary artery disease. Long-term CASS experience. Circulation 1995; 91:2325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/13\">",
"      Chaitman BR, Davis K, Fisher LD, et al. A life table and Cox regression analysis of patients with combined proximal left anterior descending and proximal left circumflex coronary artery disease: non-left main equivalent lesions (CASS). Circulation 1983; 68:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/14\">",
"      Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. Circulation 1995; 91:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/15\">",
"      Hamilos M, Muller O, Cuisset T, et al. Long-term clinical outcome after fractional flow reserve-guided treatment in patients with angiographically equivocal left main coronary artery stenosis. Circulation 2009; 120:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/16\">",
"      Fassa AA, Wagatsuma K, Higano ST, et al. Intravascular ultrasound-guided treatment for angiographically indeterminate left main coronary artery disease: a long-term follow-up study. J Am Coll Cardiol 2005; 45:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/17\">",
"      de la Torre Hernandez JM, Hern&aacute;ndez Hernandez F, Alfonso F, et al. Prospective application of pre-defined intravascular ultrasound criteria for assessment of intermediate left main coronary artery lesions results from the multicenter LITRO study. J Am Coll Cardiol 2011; 58:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/18\">",
"      Abizaid AS, Mintz GS, Abizaid A, et al. One-year follow-up after intravascular ultrasound assessment of moderate left main coronary artery disease in patients with ambiguous angiograms. J Am Coll Cardiol 1999; 34:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/19\">",
"      Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med 2011; 364:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/20\">",
"      Morice MC, Serruys PW, Kappetein AP, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation 2010; 121:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/21\">",
"      Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/22\">",
"      Lee MS, Kapoor N, Jamal F, et al. Comparison of coronary artery bypass surgery with percutaneous coronary intervention with drug-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 2006; 47:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/23\">",
"      Chieffo A, Morici N, Maisano F, et al. Percutaneous treatment with drug-eluting stent implantation versus bypass surgery for unprotected left main stenosis: a single-center experience. Circulation 2006; 113:2542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/24\">",
"      Palmerini T, Marzocchi A, Marrozzini C, et al. Comparison between coronary angioplasty and coronary artery bypass surgery for the treatment of unprotected left main coronary artery stenosis (the Bologna Registry). Am J Cardiol 2006; 98:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/25\">",
"      Seung KB, Park DW, Kim YH, et al. Stents versus coronary-artery bypass grafting for left main coronary artery disease. N Engl J Med 2008; 358:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/26\">",
"      Chieffo A, Meliga E, Latib A, et al. Drug-eluting stent for left main coronary artery disease. The DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. JACC Cardiovasc Interv 2012; 5:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/27\">",
"      Park DW, Kim YH, Yun SC, et al. Complexity of atherosclerotic coronary artery disease and long-term outcomes in patients with unprotected left main disease treated with drug-eluting stents or coronary artery bypass grafting. J Am Coll Cardiol 2011; 57:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/28\">",
"      Jang JS, Choi KN, Jin HY, et al. Meta-analysis of three randomized trials and nine observational studies comparing drug-eluting stents versus coronary artery bypass grafting for unprotected left main coronary artery disease. Am J Cardiol 2012; 110:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/29\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:e574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/30\">",
"      Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31:2501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/31\">",
"      Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Kolh P, et al. Guidelines on myocardial revascularization. Eur J Cardiothorac Surg 2010; 38 Suppl:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/32\">",
"      Park SJ, Kim YH, Lee BK, et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J Am Coll Cardiol 2005; 45:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/33\">",
"      Valgimigli M, van Mieghem CA, Ong AT, et al. Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation 2005; 111:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/34\">",
"      Chieffo A, Stankovic G, Bonizzoni E, et al. Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation 2005; 111:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/35\">",
"      Erglis A, Narbute I, Kumsars I, et al. A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. J Am Coll Cardiol 2007; 50:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/36\">",
"      Kim YH, Park DW, Lee SW, et al. Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents. Circulation 2009; 120:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/37\">",
"      Buszman PE, Buszman PP, Kiesz RS, et al. Early and long-term results of unprotected left main coronary artery stenting: the LE MANS (Left Main Coronary Artery Stenting) registry. J Am Coll Cardiol 2009; 54:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/38\">",
"      Mehilli J, Kastrati A, Byrne RA, et al. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 2009; 53:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/39\">",
"      Lee JY, Park DW, Yun SC, et al. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry. J Am Coll Cardiol 2009; 54:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/40\">",
"      Valgimigli M, Malagutti P, Aoki J, et al. Sirolimus-eluting versus paclitaxel-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: a combined RESEARCH and T-SEARCH long-term analysis. J Am Coll Cardiol 2006; 47:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/41\">",
"      Toyofuku M, Kimura T, Morimoto T, et al. Three-year outcomes after sirolimus-eluting stent implantation for unprotected left main coronary artery disease: insights from the j-Cypher registry. Circulation 2009; 120:1866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/42\">",
"      Baim DS, Mauri L, Cutlip DC. Drug-eluting stenting for unprotected left main coronary artery disease: are we ready to replace bypass surgery? J Am Coll Cardiol 2006; 47:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/43\">",
"      Valgimigli M, Malagutti P, Rodriguez-Granillo GA, et al. Distal left main coronary disease is a major predictor of outcome in patients undergoing percutaneous intervention in the drug-eluting stent era: an integrated clinical and angiographic analysis based on the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) registries. J Am Coll Cardiol 2006; 47:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/44\">",
"      Vaquerizo B, Lef&egrave;vre T, Darremont O, et al. Unprotected left main stenting in the real world: two-year outcomes of the French left main taxus registry. Circulation 2009; 119:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/45\">",
"      Price MJ, Cristea E, Sawhney N, et al. Serial angiographic follow-up of sirolimus-eluting stents for unprotected left main coronary artery revascularization. J Am Coll Cardiol 2006; 47:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/46\">",
"      Chieffo A, Park SJ, Valgimigli M, et al. Favorable long-term outcome after drug-eluting stent implantation in nonbifurcation lesions that involve unprotected left main coronary artery: a multicenter registry. Circulation 2007; 116:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/47\">",
"      Chen SL, Xu B, Han YL, et al. Comparison of Double Kissing Crush Versus Culotte Stenting for Unprotected Distal Left Main Bifurcation Lesions: Results From a Multicenter, Randomized, Prospective DKCRUSH-III Study. J Am Coll Cardiol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/48\">",
"      Meliga E, Garcia-Garcia HM, Valgimigli M, et al. Longest available clinical outcomes after drug-eluting stent implantation for unprotected left main coronary artery disease: the DELFT (Drug Eluting stent for LeFT main) Registry. J Am Coll Cardiol 2008; 51:2212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/49\">",
"      Lee JY, Park DW, Kim YH, et al. Incidence, predictors, treatment, and long-term prognosis of patients with restenosis after drug-eluting stent implantation for unprotected left main coronary artery disease. J Am Coll Cardiol 2011; 57:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/50\">",
"      Anderson HV, Shaw RE, Brindis RG, et al. A contemporary overview of percutaneous coronary interventions. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). J Am Coll Cardiol 2002; 39:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/51\">",
"      Park SJ, Hong MK, Lee CW, et al. Elective stenting of unprotected left main coronary artery stenosis: effect of debulking before stenting and intravascular ultrasound guidance. J Am Coll Cardiol 2001; 38:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/52\">",
"      Takagi T, Stankovic G, Finci L, et al. Results and long-term predictors of adverse clinical events after elective percutaneous interventions on unprotected left main coronary artery. Circulation 2002; 106:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/53\">",
"      Kornowski R, Klutstein M, Satler LF, et al. Impact of stents on clinical outcomes in percutaneous left main coronary artery revascularization. Am J Cardiol 1998; 82:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/54\">",
"      Keeley EC, Aliabadi D, O'Neill WW, Safian RD. Immediate and long-term results of elective and emergent percutaneous interventions on protected and unprotected severely narrowed left main coronary arteries. Am J Cardiol 1999; 83:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/55\">",
"      Hong MK, Mintz GS, Hong MK, et al. Intravascular ultrasound predictors of target lesion revascularization after stenting of protected left main coronary artery stenoses. Am J Cardiol 1999; 83:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/56\">",
"      Ellis SG, Tamai H, Nobuyoshi M, et al. Contemporary percutaneous treatment of unprotected left main coronary stenoses: initial results from a multicenter registry analysis 1994-1996. Circulation 1997; 96:3867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/57\">",
"      Kosuga K, Tamai H, Ueda K, et al. Initial and long-term results of angioplasty in unprotected left main coronary artery. Am J Cardiol 1999; 83:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/58\">",
"      Pedrazzini GB, Radovanovic D, Vassalli G, et al. Primary percutaneous coronary intervention for unprotected left main disease in patients with acute ST-segment elevation myocardial infarction the AMIS (Acute Myocardial Infarction in Switzerland) plus registry experience. JACC Cardiovasc Interv 2011; 4:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/59\">",
"      Pappalardo A, Mamas MA, Imola F, et al. Percutaneous coronary intervention of unprotected left main coronary artery disease as culprit lesion in patients with acute myocardial infarction. JACC Cardiovasc Interv 2011; 4:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/60\">",
"      Wong SC, Sanborn T, Sleeper LA, et al. Angiographic findings and clinical correlates in patients with cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000; 36:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/20/4426/abstract/61\">",
"      Marso SP, Steg G, Plokker T, et al. Catheter-based reperfusion of unprotected left main stenosis during an acute myocardial infarction (the ULTIMA experience). Unprotected Left Main Trunk Intervention Multi-center Assessment. Am J Cardiol 1999; 83:1513.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1555 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-658DE962AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_20_4426=[""].join("\n");
var outline_f4_20_4426=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CABG VERSUS MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Significant left main disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Left main equivalent disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Indeterminate disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H266319044\">",
"      PCI VERSUS CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H266319229\">",
"      PRECOMBAT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H266319236\">",
"      SYNTAX trial subgroup analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H266319243\">",
"      Observational studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6763783\">",
"      Meta-analysis of DES versus CABG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H266319250\">",
"      Summary of evidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H266319516\">",
"      Major society guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H266319667\">",
"      PCI WITH STENTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2733901\">",
"      DES versus BMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2733923\">",
"      Comparisons of DES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2733973\">",
"      Distal versus ostial or midshaft lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H152158609\">",
"      Stenting technique for distal left main lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2734016\">",
"      Long-term outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H66437025\">",
"      Adjunctive interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H66437033\">",
"      - Circulatory assist",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H66437040\">",
"      - Debulking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H66437047\">",
"      - Dual antiplatelet therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H66437054\">",
"      - Follow-up angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Protected lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PRIMARY PCI FOR ACUTE MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1555\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1555|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/61/3038\" title=\"figure 1\">",
"      Outcome after PCI with unprotected left main lesion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31576?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15911?source=related_link\">",
"      Circulatory assist devices: Cardiopulmonary assist device and short-term left ventricular assist devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13672?source=related_link\">",
"      Clinical use of coronary artery pressure and Doppler flow measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16360?source=related_link\">",
"      Comparison of drug-eluting intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=related_link\">",
"      Exercise ECG testing to determine prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13896?source=related_link\">",
"      Intraaortic balloon pump counterpulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/27/34234?source=related_link\">",
"      Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/51/9018?source=related_link\">",
"      Medical therapy versus revascularization in the management of stable angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41142?source=related_link\">",
"      Specialized revascularization devices in the management of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=related_link\">",
"      Use of intracoronary stents for specific coronary lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_20_4427="Radiation sensitivity syndromes";
var content_f4_20_4427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genetic syndromes associated with increased sensitivity to x-radiation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Basal cell nevus syndrome (Gorlin's syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ataxia-telangiectasia (Louis-Bar syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bloom's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fanconi's anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rare variants of xeroderma pigmentosum, complementation group G",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Possibly Gardner's syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Malkinson, FD. Radiobiology of the skin. In: Fitzpatrick's dermatology in general medicine, 5th edition, Freedberg, IM, et al (Eds), McGraw Hill, New York 1999. P.1514. Copyright &copy; 1999 McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_20_4427=[""].join("\n");
var outline_f4_20_4427=null;
var title_f4_20_4428="DMARDs PI";
var content_f4_20_4428=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly used disease modifying antirheumatic drugs (DMARDs)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Generic name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sample US brand names",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Standard DMARDs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methotrexate",
"       </td>",
"       <td>",
"        Rheumatrex; Trexall",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sulfasalazine",
"       </td>",
"       <td>",
"        Azulfidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hydroxychloroquine",
"       </td>",
"       <td>",
"        Plaquenil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leflunomide",
"       </td>",
"       <td>",
"        Arava",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Azathioprine",
"       </td>",
"       <td>",
"        Imuran",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyclosporine",
"       </td>",
"       <td>",
"        Gengraf; Neoral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Biologic DMARDs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Etanercept",
"       </td>",
"       <td>",
"        Enbrel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adalimumab",
"       </td>",
"       <td>",
"        Humira",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infliximab",
"       </td>",
"       <td>",
"        Remicade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Certolizumab pegol",
"       </td>",
"       <td>",
"        Cimzia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Golimumab",
"       </td>",
"       <td>",
"        Simponi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anakinra",
"       </td>",
"       <td>",
"        Kineret",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abatacept",
"       </td>",
"       <td>",
"        Orencia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rituximab",
"       </td>",
"       <td>",
"        Rituxan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tocilizumab",
"       </td>",
"       <td>",
"        Actemra",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_20_4428=[""].join("\n");
var outline_f4_20_4428=null;
var title_f4_20_4429="Child abuse neglect resources A";
var content_f4_20_4429=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Child abuse and neglect resources",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Child Welfare Information Gateway",
"       </td>",
"       <td rowspan=\"2\">",
"        Child Welfare Information Gateway helps professionals locate information related to child abuse and neglect and related child welfare issues. It is a service of the Children's Bureau, within the Administration on Children, Youth, and Families, Administration for Children and Families, U.S. Department of Health and Human Services.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children's Bureau/ACYF",
"        <br/>",
"        1250 Maryland Avenue, SW",
"        <br/>",
"        Eighth Floor",
"        <br/>",
"        Washington, DC 20224",
"        <br/>",
"        800.394.3366 or 703.385.7565",
"        <br/>",
"        <a href=\"file://www.childwelfare.gov\" target=\"_blank\">",
"         www.childwelfare.gov",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        American Professional Society on the Abuse of Children (APSAC)",
"       </td>",
"       <td rowspan=\"2\">",
"        The APSAC is a nonprofit organization of professionals who work with maltreated children and their families. Members include professionals working in mental health, child welfare, law enforcement, health care, and prevention.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        940 NE 13th Street CHO 3B--3406",
"        <br/>",
"        Oklahoma City, OK 73104",
"        <br/>",
"        (405) 271-8202",
"        <br/>",
"        <a href=\"file://www.apsac.org\" target=\"_blank\">",
"         www.apsac.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Chadwick Center for Children and Families",
"       </td>",
"       <td rowspan=\"2\">",
"        The Chadwick Center for Children and Families addresses the prevention, investigation, diagnosis, treatment, and prosecution of child maltreatment, and conducts professional education and research.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children's Hospital and Health Center",
"        <br/>",
"        3020 Children's Way MC 5017",
"        <br/>",
"        San Diego, CA 92123",
"        <br/>",
"        (619) 576-5803",
"        <br/>",
"        <a href=\"file://www.rchsd.org\">",
"         www.rchsd.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Child Welfare League of America (CWLA)",
"       </td>",
"       <td rowspan=\"2\">",
"        The Child Welfare League of America is a federation of public and private non-profit agencies and organizations that serve vulnerable children and youths and their families. CWLA provides training, consultation, and technical assistance to child welfare professionals and agencies while also educating the public about emerging issues affecting abused, neglected, and at-risk children.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        440 First St., NW, Third Floor",
"        <br/>",
"        Washington, DC 20001-2085",
"        <br/>",
"        (202) 638-2952",
"        <br/>",
"        <a href=\"file://www.cwla.org\" target=\"_blank\">",
"         www.cwla.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Childhelp USA",
"       </td>",
"       <td rowspan=\"2\">",
"        Childhelp USA is a national organization that provides crisis assistance 24 hours a day, 7 days a week, as well as other counseling and referral services. Childhelp USA is dedicated to meeting the physical, emotional, educational, and spiritual needs of abused and neglected children.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15757 North 78th St.",
"        <br/>",
"        Scottsdale, AZ 85260",
"        <br/>",
"        (800) 4-A-CHILD (National Child Abuse Hotline)",
"        <br/>",
"        (480) 922-8212",
"        <br/>",
"        TDD:(800) 2-A-CHILD",
"        <br/>",
"        <a href=\"file://www.childhelpusa.org\" target=\"_blank\">",
"         www.childhelpusa.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Domestic Violence Institute (DVI)",
"       </td>",
"       <td rowspan=\"2\">",
"        The Institute is an international membership organization that provides research, public information, education, and training programs in the area of domestic violence, including child abuse.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50 South Steele St.",
"        <br/>",
"        Suite 850",
"        <br/>",
"        Denver, CO 80209",
"        <br/>",
"        (303) 322-1831",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Selected National Organizations Concerned with Child Maltreatment Resource Listing. National Clearinghouse on Child Abuse and Neglect Information (www.calib.com/nccanch/pubs/reslist/rl_dsp.cfm?subjID=10).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_20_4429=[""].join("\n");
var outline_f4_20_4429=null;
var title_f4_20_4430="Knee examination part I";
var content_f4_20_4430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53905%7EPC%2F64541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53905%7EPC%2F64541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Detailed examination of the knee part I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Examination",
"signs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pressure of the patella against the femur causing",
"retropatellar pain and crepitation**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        #1 - Patellofemoral syndrome",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Bilateral sunrise views taken",
"on one cassette to evaluate for patellar subluxation and arthritic",
"changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patellar clicking with passive flexion",
"and extension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive",
"Install's maneuver (retropatellar pain with quadriceps contraction)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medial joint line tenderness or spurring or both**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        #2 - Medial compartment",
"osteoarthritis",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Standing",
"AP of the knees on one cassette, showing narrowing of the articular",
"cartilage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stiffness or",
"incomplete flexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crepitation",
"with passive flexion and extension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heel",
"to buttock measurement differs side to side**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Knee effusion",
"       </td>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Aspiration and laboratory",
"analysis for cell count, differential, crystals, gram stain, and culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss",
"of the peripatellar dimples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Synovial",
"milking sign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ballotement sign",
"for large effusions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distension",
"of suprapatellar pouch",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystic",
"swelling over the antero- inferior portion of the patella**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Prepatellar bursitis",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Aspiration and laboratory",
"analysis for cell count, differential, crystals, gram stain, and culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No",
"loss of range of motion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thickening of the prepatellar bursa**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Chronic prepatellar bursitis",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Local anesthetic block in the",
"bursa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No loss of range of",
"motion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lateral joint line",
"tenderness or spurring or both**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Lateral compartment osteoarthritis",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Standing AP of the knees on",
"one cassette showing narrowing of the articular cartilage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stiffness",
"or incomplete flexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crepitation",
"with passive flexion and extension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenderness",
"over the medial tibial plateau, 1 and 1/2\" below the joint**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Anserine bursitis",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Local anesthetic block in the",
"bursa 2 to 3 mm above the periosteum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No",
"pain with valgus stress testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal",
"knee range of motion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A line of",
"tenderness over the medial tibial plateau extending up to or above the",
"medial joint line**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Medial",
"collateral ligament injury",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Empiric treatment with 3 to 4 weeks of straight",
"leg immobilization;",
"local anesthetic block placed just over the ligament (optional)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain aggravated by valgus stress testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain",
"aggravated by external rotation of the tibia on the femur",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ** is used to identify the hallmark sign; that is, the sign that has the greatest specificity for the diagnosis listed.",
"     <br>",
"      #1 and #2 refer to the two most common conditions affecting the knee.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Detailed examination of the knee part II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Examination signs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Confirmation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenderness over the lateral tibial plateau extending along a line to the lateral joint line**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Lateral collateral ligament injury",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Improvement with 3 to 4 weeks of straight leg immobilization; local anesthetic block placed just over the ligament (optional)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain aggravated by varus stress testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain aggravated by internal rotation of the tibia on the femur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Painful anterior drawer sign**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Anterior cruciate ligament injury",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Arthroscopy or MRI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Painful or inability to fully squat or duck waddle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Joint line tenderness and mechanical locking or joint line popping**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Meniscal tear",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Arthroscopy or MRI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inability to duck waddle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Popping with squatting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palpable cyst in the medial side of the popliteal fossa**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Baker's cyst",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Characteristic aspirate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incomplete range of motion if the cyst is large",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patellar apprehension sign with lateral subluxation**",
"       </td>",
"       <td>",
"        Patellar subluxation or dislocation",
"       </td>",
"       <td>",
"        Clinical diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lateral femoral condyle tenderness**",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Iliotibial band syndrome",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Local anesthetic block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal lateral collateral ligament examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No active evidence of lateral compartment osteoarthritis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ** Is used to identify the hallmark sign; that is, the sign that has the greatest specificity for the diagnosis listed.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_20_4430=[""].join("\n");
var outline_f4_20_4430=null;
var title_f4_20_4431="Contents: Biliary tract disease";
var content_f4_20_4431=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/12/3278\">",
"       Gastroenterology and Hepatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Biliary tract disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Biliary tract disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Ampullary neoplasms",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/52/43848\">",
"           Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/37/3674\">",
"           Ampullary carcinoma: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/20/26950\">",
"           Clinical manifestations and diagnosis of ampullary adenomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/36/13897\">",
"           Treatment of ampullary adenomas",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Biliary cysts",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/47/9977\">",
"           Biliary cysts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/53/2902\">",
"           Caroli disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Biliary tract imaging",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/24/21897\">",
"           Cholangioscopy and pancreatoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/32/18950\">",
"           Computed tomography of the hepatobiliary tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/18/5415\">",
"           ERCP after Billroth II reconstruction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/3/20536\">",
"           ERCP for biliary disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/33/24088\">",
"           ERCP for pancreatic disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/45/4822\">",
"           ERCP in children: Technique, success and complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/41/13976\">",
"           ERCP in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/19/37175\">",
"           Endoscopic balloon dilatation for removal of bile duct stones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/23/22905\">",
"           Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/55/12152\">",
"           Endoscopic management of complications from laparoscopic cholecystectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/22/19816\">",
"           Endoscopic methods for the diagnosis of pancreatobiliary neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/25/28054\">",
"           Magnetic resonance imaging of the hepatobiliary tract",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/49/39705\">",
"           Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/39/37491\">",
"           Percutaneous transhepatic cholangiography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/47/18166\">",
"           Percutaneous transhepatic cholangioscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/38/26216\">",
"           Post-ERCP bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/63/28666\">",
"           Post-ERCP pancreatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/38/20072\">",
"           Post-ERCP perforation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/10/25767\">",
"           Precut (access) papillotomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/44/7882\">",
"           Rare complications of ERCP",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/62/10214\">",
"           Standard biliary sphincterotomy technique: The cutting edge",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/30/21992\">",
"           Ultrasonography of the hepatobiliary tract",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Biliary tract infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/29/26069\">",
"           AIDS cholangiopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/13/24790\">",
"           Acute cholangitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/6/42087\">",
"           Endoscopic diagnosis and management of biliary parasitosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/51/23351\">",
"           Magnetic resonance cholangiopancreatography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/25/23959\">",
"           Post-ERCP septic complications",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cholecystitis and other gallbladder disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/37/6742\">",
"           Acalculous cholecystitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/36/12874\">",
"           Clinical manifestations and diagnosis of sphincter of Oddi dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/22/18792\">",
"           Complications of laparoscopic cholecystectomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/0/8200\">",
"           Functional gallbladder disorder in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/57/13209\">",
"           Gallbladder polyps and cholesterolosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/33/29208\">",
"           Pathogenesis, clinical features, and diagnosis of acute cholecystitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/47/39668\">",
"           Porcelain gallbladder",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/9/15511\">",
"           Treatment of acute cholecystitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/28/29126\">",
"           Treatment of sphincter of Oddi dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/0/22534\">",
"           Xanthogranulomatous cholecystitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gallstones",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/8/10374\">",
"           Approach to the patient with incidental gallstones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/24/21897\">",
"           Cholangioscopy and pancreatoscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/16/6408\">",
"           Dissolution therapy for the treatment of gallstones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/35/12854\">",
"           Electrohydraulic lithotripsy in the treatment of bile and pancreatic duct stones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/23/22905\">",
"           Endoscopic management of bile duct stones: Standard techniques and mechanical lithotripsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/24/4489\">",
"           Epidemiology of and risk factors for gallstones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/62/26598\">",
"           Gallstone ileus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/29/16856\">",
"           Laser lithotripsy for the treatment of gallstones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/33/44565\">",
"           Mirizzi syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/15/14582\">",
"           Patient selection for the nonsurgical treatment of gallstone disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/47/18166\">",
"           Percutaneous transhepatic cholangioscopy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/10/25767\">",
"           Precut (access) papillotomy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/33/27157\">",
"           Precut sphincterotomy: Another perspective on efficacy and complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/5/7254\">",
"           Precut sphincterotomy: Another perspective on indications and techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/8/14472\">",
"           Recurrent pyogenic cholangitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/62/31722\">",
"           Uncomplicated gallstone disease in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Malignant diseases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/52/43848\">",
"           Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/43/40633\">",
"           Clinical manifestations and diagnosis of cholangiocarcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/22/19816\">",
"           Endoscopic methods for the diagnosis of pancreatobiliary neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/54/43881\">",
"           Epidemiology, pathogenesis, and classification of cholangiocarcinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/33/25114\">",
"           Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Primary sclerosing cholangitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/63/22521\">",
"           Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/25/40342\">",
"           Colorectal cancer and primary sclerosing cholangitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/32/35334\">",
"           Epidemiology and pathogenesis of primary sclerosing cholangitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/8/41097\">",
"           Treatment of primary sclerosing cholangitis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-2E2E9E1B8C-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f4_20_4431=[""].join("\n");
var outline_f4_20_4431=null;
